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Abstract
Genetic and epigenetic changes that occur in the cell induce oncogenic transformation and 
increased cell migration resulting in metastasis. We studied molecular mechanisms that 
involve migratory protein, Rhamm-induced cell transformation by overexpressing it in 
10T1/2 cells. We demonstrated that Rhamm isoform Al63, induces cell resistance to anoikis 
and to growth inhibitory signals through an ERK1,2 dependent mechanism by assessing 
foci and colony formation in soft agar. We also showed that this isoform of Rhamm 
exhibits different subcellular localization than Rhamm full lenght (RhammFL). These 
differences may account for the oncogenic activity of RhammA163. Additionally, we 
assessed CD151 immunoreactivity in prostate cancer tissues by using an anti-migratory 
mAb, 1A5, and found that positive CD151 staining predicts early biochemical failure and 
metastasis in these patients. These studies increased the understanding of the molecular 
mechanisms that involve tumour progression and identified a subcellular population of 
CD151 that associates with poor outcome in prostate cancer.
Keywords: CD151, Full Length RHAMM, RHAMMa163, cell migration, oncogenic 
transformation, prognostic factor, prostate cancer, subcellular localization, metastasis
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The tightly regulated steps of cell migration break down during tumor formation from 
genetic and epigenetic changes that occur in the cell. This deregulation induces cell 
plasticity, growth and survival, and increases cell migratioa Cells begin to ignore 
inhibitory signals and grow in the absence of optimal substrate during the early steps of 
transformation [1]. As transformation influences proteins associated with cell migration, 
cells become more migratory and may eventually give rise to single cells that grow 
uncontrollably to form a tumour and later on migrate away from it to grow at a distant site 
to create metastases [1-3].
Normal cell migration is an important function for the formation and differentiation of 
tissues in the embryo. Later in the adult life, cell migration promotes wound healing, 
tissue remodelling and immune responses. Pathologic cell migration contributes to 
processes such as inflammation, autoimmune disease and tumour progression, among 
others [2, 4-6]. An important regulator of cell migration is the Receptor for Hyaluronan 
Mediated Motility, RHAMM. Of the various isoforms of RHAMM (Rhamm for the 
mouse version) only some are associated with aggressive behaviour in cancer cells [7]. 
Specifically, overexpression of RhammA163 transforms mesenchymal cells [8]. As a last 
step towards understanding how RHAMM performs oncogenic functions, we compared 
subcellular compartmentalization and transforming functions of RhammA163 with the full-
1
length protein. RhammA163 had different localization in the cell and significantly higher 
transformation potential which was dependent on its association with ERK1,2.
Cell migration and cancer metastasis is also regulated by tetraspanin CD151 [9-13]. 
CD151 is a transmembrane protein linked to poor outcome in many cancers [14-17], It 
predominantly localizes to the plasma membrane [18, 19] were it binds integrins in 
tetraspanin enriched microdomains to influence cell adhesion, migration and proliferation 
[20, 21]. In this study, we assessed the relationship between CD151 mRNA levels and 
protein expression in normal prostate epithelium versus metastatic prostate cancer. Patient 
information collected from multiple databases showed that CD151 levels remain stable 
during prostate cancer stages [22-25]. However, a CD151 mAb that suppresses cell 
migration and stromal invasion in human epidermoid carcinoma cells, HEp 3 cells [26], 
recognized a subpopulation of CD151 associated with poor prognosis in prostate cancer. 
CD151 immunoreactivity predicted early biochemical recurrence and metastasis.
1.2 Cancer and metastasis as a multistep process
1.2.1 Oncogenic transformation overview
During the cell cycle a series of events lead to cell replication to maintain tissue 
homeostasis with normal cell turnover [27]. Normally, there is a delicate balance of 
growth-inducing signals that promote the cell cycle and proliferation [3, 28]. Oncogenes 
help to coordinate the cell cycle and may encode growth factors, growth factor receptors, 
regulators of chromatin, transcription factors, signal transducers and/or regulators of
2
apoptosis [29]. During cancer progression, oncogenes are often hyper-activated by point 
mutations, chromosomal rearrangement, or gene amplification, leading to overexpression 
and deregulatioa This can promote survival and/or growth advantages, cell 
transformation, and tumour formation [29, 30].
Cell transformation and cancer formation is a complex, multistep process [1], Cancer 
cells must grow independently of correct growth signals, resist antigrowth or proapoptotic 
signals, replicate, and induce new blood vessel formatioa In order to metastasize, they 
must additionally migrate and invade through surrounding tissue [1, 3]. Transforming 
cells produce their own mitogenic factors, overexpress growth factor receptors, and 
induce growth factor production by neighbouring cells. Some cells even induce export of 
proteins/receptors that normally function intracellularly. For example, hepatocytes exhibit 
autocrine production of TGFp to become resistant to apoptosis and attain EMT properties
[31], breast cancers increase Hyaluronan (HA) synthesis [32], and Ras transformed 
mouse fibroblasts overexpress the putative oncogene, RHAMM [33]. In addition, during 
oncogenesis and wound repair, cytoplasmic proteins such as RHAMM are transported to 
the plasma membrane where they couple with CD44 to promote genomic instability and 
tumour progression [34], De-regulation or altered expression of transmembrane proteins 
and extracellular receptors such as tetraspanins also influence cellular transformation. For 
instance, during colon cancer progression, downregulation of tumour suppressor CD63 
takes place [35]. Transforming cells are also capable of inducing constitutive activation of 
oncogenes such as Ras that, in turn, end up triggering mitogenic pathways, such as the 
Ras/MEK1/ERK1,2, [36] that results in tumour formatioa Conversely, overexpression of
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integrins such as a6p4 induces resistance to anoikis in breast tumours [37]. This induces 
phenotypical changes that lean the cell towards a highly proliferative phenotype.
Second to this self sufficiency in growth signals is the resistance to anti-growth signals. In 
general, cells receive cues from the surrounding microenvironment that dictate their 
entrance into the active cell cycle, thus maintaining tissue homeostasis [27, 28]. These 
cues induce cell quiescence, halting the cells in the G0 state of the cell cycle until new 
pro-growth signals are sensed [27, 28]. During tumour progression the anti-growth cues 
are ignored by the cell by a number of mechanisms that involve loss, downregulation, 
and/or mutation of tumour suppressor genes [1, 3, 38, 39]. Perhaps the most studied 
illustration o f this could be retinoblastoma protein/gene (pRb) which inhibits cell 
proliferation by affecting the availability and activity o f transcription factors in charge of 
induction of the cell cycle progression [39-41]. Mutation of the RBI family induced loss 
of contact inhibition and sphere formation in Ras transformed mouse fibroblasts [42]. 
Moreover, injection of these spheres into nude mice caused tumour formatioa
Cancer cells must ignore programmed cell death/apoptosis in order to thrive as a 
malignant tumour. Normal cells that are correctly in tune with environmental cues 
undergo apoptosis in response to apoptotic signals. Extracellular cues include IGF, IL-3 
(sensed by their cognate receptors in the plasma membrane), hypoxia, and cell-cell/cell- 
matrix adherence signals [1]. Loss of epithelial cell-extracellular matrix interactions 
affects gene regulation, differentiation, and cell proliferation resulting in cellular 
imbalance and tissue disorganization that elicits a series of similar intracellular cues [1,3] 
that upon detection promote a finely regulated process of orchestrated cell death, anoikis. 
Oncogene overexpression can provide protection against this [43]. For instance,
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overexpression of the anti-apoptotic gene bcl-2 protected fibroblasts and transformed 
epithelial cells [44], Resistance to anoikis is crucial during tumour progression in cases 
such melanoma [45], ovarian [46], oral [47], and prostate cancer [48].
The final, and arguably the deadliest, characteristic that a cancer cell acquires, is its 
ability to invade surrounding tissue and metastasize to distant sites [1], During metastasis, 
a cell must detach from the primary tumour, migrate and invade into surrounding tissue, 
intravasate into the vasculature, extravásate and ultimately grow as a metastatic nodule in 
a distant site [49]. Various modifications in gene regulation and, therefore, in protein 
expression regulate these steps in metastasis. Cancer cells can activate, overexpress, or 
even export proteins that act as receptors or transmembrane scaffolds that activate cell 
transformation and increase cell migratioa Oncogenes, besides their activity as growth 
factors, growth factor receptors, regulators of chromatin, transcription factors, signal 
transducers and/or regulators of apoptosis [29], are important regulators of cell migratioa 
The ability of oncogenes to influence so many stages of metastatic cancer formation 
makes them likely candidates for intervention and as biomarkers.
1.2.2 Cell migration and cancer
Migration in response to specific stimuli is a common feature among cells. Normally cell 
migration occurs during embryogenesis and morphogenesis, when cells migrate to 
generate the three layers of the embryo and to form differentiated tissues. In adults, cell 










Figure 1.1 Steps for cell transformation and tumour progression
responses. Migratory events are usually tightly regulated. Disrupted and/or pathologic 
cell migration plays a central role in diseases such as chronic inflammation, vascular 
disease, autoimmune disorders, osteoporosis, tumour progression and metastasis [2, 4, 5],
Cell migration is often initiated via intricate signalling pathways originating at the cell 
membrane where many surface receptors, such as integrins or growth factor receptors,
Loss of contact inhibition
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become activated. This, in turn, induces signaling cascades that often act through 
regulation o f the Rho family of small GTPases. A subset of the Ras superfamily, the Rho 
GTPases include Cdc41, Rac, and Rho A which are important regulators of actin. In 
response to activation of cell surface receptors, Rho GTPases influence cell migration by 
regulating actin, tubulins, the phospholipid enzyme phosphoinositide 3-kinase (PI3K), 
Akt, and vesicular transport [2, 50, 51]. Cell migration can be turned on and off by 
changes in the expression of adhesion receptors, cytoskeletal-linking proteins, and 
extracellular matrix (ECM) ligands.
During cell migration, the cell first polarizes and extends protrusions (lamellipodia or 
filopodia) towards the migration front. After these protrusions form, they attach the cell to 
the extracellular matrix to provide stability. The cell forms adhesion sites known as focal 
complexes at its leading edge. Integrins are members of the focal complex and support 
adhesion to the underlying ECM. Integrins promote maturation of focal complexes into 
focal adhesions, which adhere strongly and inhibit cell translocatioa Adhesion sites at 
both the front and rear of the cell must assemble and disassemble, respectively in order to 
allow the cell to form new protrusions at the leading edge and to detach from the rear in a 
cyclical process influenced by chemotactic and haptotactic stimuli [2].
Cancer cell migration is enhanced by communication between the tumour and its 
microenvironment (TME). The expression of TME components facilitates tumour cell 
motility. Tumour associated cells including adipocytes, fibroblasts, stromal cells, immune 
cells, and endothelial cells, overexpress multiple growth factors (namely EGF, PDGF, 
and VEGF) and chemokines (such as SDF1 and CXCL12) that act as chemoattractants.
7
Stromal cells secrete EGFLs, ILs, TNFs, and growth factors such as TGF-P, VEGF, FGF- 
7, and IGF-2, which bind cancer cell receptors to activate cancer cell migration. These 
factors also stimulate cancer cell expression of cytokines that attract and stimulate 
proliferation of tumour associated stromal cells (TASCs). This paracrine positive 
feedback loop supports a pro-migratory environment for cancer cells.
Cancer cells take advantage of the pro-migratory TME by increasing their expression of 
ECM receptors that bind components of the modified TME [52]. Integrins, are key 
regulators of cell-ECM interactions and changes in their expression influences cancer cell 
fate. In particular, integrins such as avP3, a3pi, a6p4 [53, 54] promote tumourigenic and 
metastatic phenotypes. Other cell surface receptors can be affected. RHAMM, which 
interacts with HA and forms complexes with transmembrane receptors such as CD44, 
PDGFR, and RON [55] is not an integrin, but promotes migration of many types of 
cancer cells. Given this function, it is not surprising that RHAMM protein and mRNA 
levels are increased in most human cancers and high levels of expression are prognostic 
of poor outcome in subsets of breast cancer [56, 57], gastric cancer [58], multiple 
myeloma [59], and colorectal cancer [60, 61].
A significant number of publications have compared gene expression profiles in normal 
cells with cancer cells [62, 63]. Cancer cells often overexpress pro-migratory genes and 
therapies that inhibit their motility result in a more compact, less metastatic tumor. 
Moreover, genes expressed during embryogenesis and early development are turned on 
during tumourigenesis giving rise to more motile and highly aggressive cells [64],
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Epithelial cell markers are downregulated and mesenchymal genes are overexpressed 
promoting plasticity and motility. These genetic changes contribute to cancer cells that 
can invade locally and metastasize [62, 65, 66].
Genetic de-regulation
Figure 1.2 Steps for cell invasion and metastasis
There is a common theme throughout the above mentioned processes: outside-in 
signalling determined and activated by proteins present in the cell membrane. Enhanced 
tumour cell migration results from the integration of multiple factors rather than changes 
in a few or a single protein. In order to study the mechanisms that influence oncogenicity 










RHAMM and CD151, that act as scaffolds to tether many other proteins into complexes 
localized to specific areas of the cell and that activate signalling cascades and regulate the 
motile cycle of polarization, protrusion formation, retraction and displacement. RHAMM, 
a member of the hyaladherin family of hyaluronan binding proteins, was chosen as an 
example o f a motogenic protein that forms complexes with multiple signalling pathways 
and that is necessary for cell polarity [67], dynamic nature of leading lamellae and 
dynamic instability of microtubules. Another example is the transmembrane protein 
CD151, a member of the tetraspanin family that scaffolds integrins with multiple proteins 
forming tetraspanin-enriched microdomains in the cell membrane [20, 68]. CD151
associates with specific integrins including a3|31, a6pi, and a6|34, MMPs, and other 
tetraspanins to induce cell migration and ultimately metastasis. Even though RHAMM 
and CD151 are very different molecularly and structurally, they both promote migration 
of cancer cells and their expression is prognostic of poor clinical outcome in a number of 
human cancers. RHAMM participates in regulation of cell polarity, the turnover of focal 
adhesions, and the formation of membrane extensions through microtubules and CD151 
is involved in cell adhesion, hemidesmosome formation, and retraction of the rear of the 
cell.
1.3 The role of RHAMM in cell migration and cancer progression
1.3.1 RHAMM structure
RHAMM/HMMR (Receptor for Hyaluronan Mediated Motility), is a Hyaluronan (HA) 
receptor, which was the first cellular HA binding protein isolated and purified by Dr. Eva
1 0
Turley from cultured cardiac fibroblasts [69]. RHAMM binds to HA via a coiled coil 
carboxyl terminal region that is rich in basic amino acids that possesses a B(X)7B motif.
RHAMM is a largely coiled coil protein that does not contain a transmembrane domain or 
classical export signal and is likely exported through an unconventional mechanism that 
does not involve the golgi/ER. RHAMM is comprised of 18 exons located in 
chromosome 11 in mice; its mRNA transcript encodes a 95kDa protein. In humans, 
RHAMM is found on chromosome 5 translatede into an 85 kDa protein. Intriguingly, the 
latter chromosome homes multiple disease associated genes [70]. RHAMM is expressed 
as multiple isoforms that consist mainly of shorter forms that lack a number of amino 
acids in the N-terminus o f the protein of 60-73 kDa [136]. Exon 4 is responsible for 
interphase microtubule binding and exon 13 is at least partially responsible for 
centrosomal localization. Its C-terminus, after aa 600, is also involved in association with 
mitotic spindles (figure 3). RHAMM also shares high homology with Klp2 in the 
carboxy-terminal, which is a site of indirect interaction with the dynein/dynactin complex 
[71]. RHAMM is a ubiquitous protein (for reference see HMMR gene in Gene note and 
GNF BioGPS databases) found intracellularly as well as extracellularly, and exported in 
response to cell stress [72, 73]. It occurs mainly in fibroblasts, immune cells, smooth 
muscle cells, endothelial cells, sperm and keratinocytes [74-79]. Subcellularly, it is 
distributed at the cell surface, mainly in podosomes and other membrane protrusions, in 
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Figure 1.3 Rhamm schematic. Rhamm FL gene encodes a 794 amino acid protein in 
mice. The translated coiled coil protein possesses two tubulin binding sites: the one in the 
N-terminus associates with interphase microtubules whereas the C-terminus one has been 
linked to the centrosomes. One of the most studied isoform lacks the first 163 amino acids 
in the N-terminus of the protein, but conserves the C-terminal sequence. Bottom: 
predicted coil distribution.
1.3.2 The role of RHAMM in cell migration
1.3.2.1 RHAMM -  HA interactions
RHAMM functions in cell migration are highly dependent on its interactions with HA. 
Briefly, HA is a glycosaminoglycan composed of repeating units of A-acetyl glucosamine 
and (3-glucuronic acid. The functions of HA within the ECM and cells depend upon its 
molecular weight, the type of cell, and the HA receptor(s) that target cells express. HA 
fragments provide signalling functions and are usually present during the ECM 
remodelling that is associated with morphogenesis, wound healing, or disease. Cancer 
cells are particularly adept at producing and responding to HA fragments [83-85]
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(reviewed in InTech Ward C, Vasquez C et al, in press). RHAMM detects HA 
oligosaccharides and fragments triggering multiple signalling pathways that result in 
increased cell motility.
Evanko SP et al. postulated that RHAMM, at least partially, regulates uptake and 
translocation o f HA to the nuclear and perinuclear area, contributing to an HA dependent 
increase in cell motility, as well as cell cycle regulation, mitosis and RNA splicing [86]. 
In this study, HA was found nearby microtubules of Human Smooth Muscle cells (SMCs) 
in vesicle-like organelles. RHAMM was surrounded by these structures in the 
microtubules of SMCs. Moreover, fluorescein labelled HA bound to microtubules close 
to the nucleus that were positive for RHAMM staining. HA staining also overlapped with 
RHAMM in the mitotic spindle during mitosis. Suggesting that intracellular HA may 
contribute either actively to cell migration by modulating RHAMM function, or passively 
by balancing biomechanical characteristics that may contribute to the cell stabilization 
and force balance required during cell locomotion [86].
RHAMM dependent cell migration of arterial smooth muscle cells from rat aorta was 
demonstrated by Goueffic Y et al, 2006. Stimulation with HA induced increased cell 
migration as demonstrated by faster closing of gaps in scratch wound assays 
independently of cell proliferation. RHAMM siRNA experiments further confirmed the 
role of RHAMM in this process. The same study showed that HA promoted actin 
reorganization through RHAMM, contributing to stress fibres and lamellipodia formation 
by stimulating Rac activation in a PI3K dependent mechanism that was independent of 
RhoA [87].
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Analysis of RHAMM mRNA expression in cranial neural crest cells (CNCC) of 
Xenophus laevis embryos (African amphibian) was detectable along with CD44 and 
HAS1. However, it was also found to be expressed independently of these two genes in 
“temporal windows” where cell migration was required to continue with its development. 
Indicating thus that RHAMM performs HA dependent and independent functions in 
development [88]. Interestingly, CD44 surface display is reduced in mesenchymal cells 
isolated from RHAMM-/- mice, demonstrating functional interplay between these two 
HA receptors [89]. Moreover, in CD44-/- mice, RHAMM compensates for the deficit of 
CD44 by supporting HA engagement on the surface of the cell [90, 91].
1.3.2.2 RHAMM-ERK1,2 interactions
ERK1,2 has an extensive effect on cell migration that can be dependent on Ras activation 
and on integrin signalling but also cooperate with growth factor receptors through a 
mechanism that does not require Ras-Raf phosphorylation [92]. Not coincidentally, 
Hatano et a i, in 2010 demonstrated that RHAMM not only associated with ERK1,2, but 
also was required for ERK1,2 activation through a pathway different than Raf-MEK - 
ERK in HCF (human cementifying fibroma cells) and 10T1/2 mouse fibroblasts [93]. 
This suggests that RHAMM contributes to pERKl,2 induced cell migration through a 
different mechanism [94]. Furthermore, the presence of RHAMMa163 was required for 
ERK activation in response to PDGF in 10T1/2 cells. Levels of RHAMM in the 
membrane were directly correlated with the degree of ERK phosphorylation [93].
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Rhamm/ERK1,2 interactions in cell migration were further demonstrated in our lab by 
using a Rhamm -/- mouse model created in our laboratory. Gene deletion was performed 
by homologous recombination of exons 8-16, generating mice with viable offspring; 
although with reduced fertility [95]. Additional studies showed that Rhamm -/- MEFs 
(Mouse Embryonic Fibroblasts) respond less to growth factors than corresponding 
wildtype. Further characterization of Rhamm -/- phenotypes, performed by Tolg et al, 
2006 showed that knocking out Rhamm expression in MEFs significantly reduced their 
ability to close the gap in scratch wound assays and 3D collagen gel assays when 
compared with Rhamm expressing cells. They also demonstrated that Rhamm not only 
played a role in ERK activation, but had an additional influence in sustaining ERK1,2 
phosphorylation as demonstrated by ELISA, Western Blotting and confocal imaging. 
Moreover, a MEK inhibitor, U0126, blocked motility in response to HA and serum 
stimulation of Rhamm -/- cells that were rescued for RhammFL expression but not 
Rhamm -/- [89], The same was true when CD44 was blocked indicating that there is 
interplay between these two Rhamm receptors. Further addition of MEK restored 
migration of Rhamm -/- cells suggesting that Rhamm-MEK/ERK interactions are 
important for cell migratioa This activation of ERK1,2 by growth factors required 
CD44/RHAMM interactions.
1.3.2.3 RHAMM and the cytoskeleton
Besides Rhamm/ERK interactions, Rhamm binds to many other proteins in the context of 
cell migration. It has been shown by immunoprécipitation that during the M phase
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Rhamm binds to the dynein/dynactin motor complex previously described as an important 
player in cell migration that transports cellular cargo by walking along cytoskeletal 
microtubules towards the minus-end of the microtubule [71]. Moreover, Rhamm shares 
high homology with Klp2 in the carboxyl-terminus. This Klp2 is a site of indirect 
interaction with the dynein/dynactin complex. Also, Exon 4 was shown to be responsible 
for interphase microtubule binding and amino acids 704-707 were suggested to have 
homology with TPLK consensus cdc2 phosphorylation site. RHAMM is a tubulin binding 
protein that possesses two microtubule binding sequences, one for interphase 
microtubules present at exon 4 in full length RHAMM and a mitotic microtubule binding 
site present at the very C-terminus of the sequence [78, 80].
Turley and others have demonstrated that RHAMM specific antibodies blocked HA 
dependent migration on different cell lines. Upon binding of RHAMM to HA, a number 
of signaling events including protein tyrosine phosphorylation of several intracellular 
proteins take place. For instance, RHAMM was necessary for c-src-induced rescue of 
cell motility in c-src -/- mouse fibroblasts; suggesting Rhamm as an upstream activator of 
c-src [96]. Additionally, there is evidence that HA induced a significant increase in 
locomotion o f C3 cells (mouse H-ras transformed fibroblasts) by inducing a rapid but 
transient phosphotyrosine activity, including FAK, that localized mostly to the forming 
lamellae in cells stimulated with HA followed by focal adhesion turnover [97], HA- 
mediated cell motility was diminished by the use of inhibitors of the kinase activity. 
Moreover, mutation o f the HA binding sites in RHAMM not only reduced protein 
tyrosine phosphorylation and focal adhesion formation but also reverted ras-induced 
transformation [8]. These and other studies clearly demonstrate the role of ppl25FAK in
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addition to the proto-oncogene pp60c'src in the induction of rearrangements in actin 
filament and cell-matrix adhesion structures that account for cell locomotion in response 
to HA/RHAMM interactions [97]. In relation to this, Kaverina et al, 2002 postulated that 
RHAMM contributes to the microtubule instability by inducing their repeated contact 
with focal adhesions, which promoted microtubule disassembly [90].
The importance of RHAMM in maintaining the integrity of focal adhesions and filopodia 
by transducing the effects of pericellular HA in human esophageal squamous cell 
carcinoma cell line (ESCC), OSC1, was also demonstrated recently by Twarock et al. 
HA was proven to be important in cell morphology, actin cytoskeleton, filopodia, and 
focal adhesion complexes in that cell line. Total and pFAK, as well as pERK levels 
decreased after inhibition of HA. The same was true for other ESCC cell lines. This 
resulted in a significant decrease in cell migration and proliferation. RHAMM knock 
down by shRNA experiments led to inhibition of filopodia and reduction of FAK, 
Akt/PKB phosphorylation, and reduction of pERK levels [98].
1.3.2.4 RHAMM -  integnn interactions
RHAMM induced weak integrin avidity to assist in the process of cell migration. In 1998, 
Gares SL et al, demonstrated that thymocyte migration and adhesion were regulated at 
least in part by fibronectin and its receptors a4/5 (M integrins in a RHAMM mediated 
mechanism, suggesting a functional association between RHAMM and pi integrins [99]. 
Adherence o f MN (multi-negative progenitor) thymocytes to fibronectin was blocked by 
a mAb to a5/pi. RHAMM did not participate in thymocyte adhesion to fibronectin under
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conditions of minimal shear. However, it participated and was needed, in conjunction 
with a4,5/pi, for cell motility. The latter were dominant over RHAMM in this process. 
Thymocytes produced their own HA and it was required for cell migration [100]. Later, 
Gares and Pilarski showed that a4,5/pi regulated RHAMM expression during 
differentiation of thymocytes [101].
1.3.3 The importance of RHAMM in cancer
RHAMM is a novel breast cancer susceptibility gene that antagonizes BRCA1 [55, 102] 
and is prognostic factor for poor outcome [59], It is overexpressed in 50% of breast 
cancers, which positions it on the list of the top 10% relevant breast cancer oncogenes, 
among BRCA1,2, HER2, ER, PR, among others. In a different model, after Ras induced 
transformation of mouse fibroblasts, there was evidence of a clear increase in a form of 
Rhamm, an N-terminal truncation that lacks the first 163 aa residues (RhammA163). This 
isoform was not only required for Ras transformation but is also transforming in 
mesenchymal cells [8], strongly suggesting that Rhamm is an oncogene. On the cell 
surface RHAMM interacts with HA and forms complexes with other transmembrane 
receptors such as CD44, PDGFR, RON, integrins, etc. [55, 99-101] which results in the 
activation of several signalling pathways, some of which were discussed above, that 
influence among others, cancer progression and metastasis.
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Figure 1.4 RHAMM participation in cell migration pathways. Once Rhamm binds 
with HA and/ or growth factors, a series of signalling pathways are activated to promote 
cell migration. Top: schematic of some of the multiple pathways that Rhamm influences 
on in terms of locomotion. Bottom: Once the cell gets in contact with “clues”, growth 
factors, cytokines, Ca++, etc., its cell receptors orient towards the signal and the 
migration steps take place. RHAMM participates in regulation of cell polarity, the 
turnover of adhesions, and the formation of membrane extensions through microtubules.
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RHAMM is elevated in most types of cancer in particular breast [56, 57], glioma [103], 
endometrial [104], colorectal [60, 61], stomach [58], and prostate cancer [105], as well as 
in MM [59] and AML [106]. Consistent with these clinical correlations, RHAMM has 
tumourigenic properties in experimental systems that have been linked to its ability to 
bind to HA. In BCA cells, RHAMM/CD44/HA complexes sustain 
phosphorylation/activation of the Ras/MAPK (ERK1,2) signalling pathway, leading to 
BCA progression and constitutively high rates of motility and invasion [7]. The 
relationship between RHAMM and ERK1,2 activation has recently been confirmed in 
BCA samples where concomitant upregulation of phosphorylated ERK1,2 and RHAMM 
in tumour samples correlates with a high tumour grade (Ward C. in preparation).
1 .4  CD151 in cell migration and cancer progression
1.4.1 CD151 structure
CD151 (GP27, SFA-1, PETA-3) is one of 33 members of the mammalian tetraspanin 
family. The human CD151 gene is located on chromosome 1 lp l5.5 and composed of 9 
exons, but the protein is encoded by exons 3 to 9 and is translated into 253 amino acids 
(Figure 1.5A). It was first identified by Ashman LK et al in 1991 in acute myeloid 
leukemia cells as a 27kDa platelet surface glycoprotein [107]. There may be alternative 
splicing of exon 2 in the 5’UTR in humans, varying the length of the mRNA transcript 
[108]. It is characterized by four transmembrane domains, a large extracellular loop 
(LEL), small extracellular loop (SEL), and the N and C terminal as two small intracellular 
tails. The later allocates the YXX(J) motif, relevant for internalization of CD151 and its
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binding partners. The LEL is perhaps the most studied sequence of CD151 since it 
confers it with binding specificity. The reason for this is that it contains the QRD motif 
between amino acids 194-196, which is responsible for strong and stable binding with the 
integrin a3p i. The importance o f this interaction will be discussed below. Within the LEL 
there are also two di-sulphide bridges that stabilize the protein folding in this area. CD151 
can undergo post-translational modifications such as N-linked glycosylation, producing a 
larger protein of 32kDa. Moreover, CD151 possess 6 palmitoylation sites which are of 
pivotal importance for CD151 interaction with other tetraspanin members and other 
proteins and also stabilization of the molecule by diminishing lysosomal degradation 
(Figure 1.5B) [20]. It is ubiquitously expressed in humans (for reference see CD151 gene 
in Gene note and GNF BioGPS databases), but is predominantly found in the plasma 
membrane of epithelial cells, endothelial cells, smooth muscle cells, and platelets [11, 18- 
20]. Subcellular localization of CD151 ranges from hemidesmosomes [19], to plasma 
membrane, endosomes, and endothelial cell junctions [18, 19].
1.4.2 The role of CD151 in cell migration
1.4.2.1 CD151 and integrins
Integrins play an important role in cell migration by activating many signalling pathways 
that lead to a transformation in cell shape, increase or decrease in cell adhesions to other 
cells and to the ECM (this is highly dependent on its binding partners and the context of 
the microenvironment since different isoforms/chains of integrins bind to different 
substratum i.e. a3/6pi bind to laminin 5 present mostly in the basement membrane), and
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ultimately in cell migration. For instance, CD151 modulates MDA-MB-231 cell 
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Figure 1.5 CD151 gene and protein schematic. CD151 gene is composed of 9 exons, 
from which only exons 3-9 get translated (A). The protein encoded spans the plasma 
membrane four times, possesses 2 intracellular tails, two extracellular loops, 6 
palmitoylation sites, and one glycosylation site, (B).
It is perhaps its association with integrins, such as a3(31, a6pi, and a6p4 that makes 
CD151 such an important mediator in cell migration and cancer progression especially in 
epithelial cells. It is, therefore, not surprising that a number of researchers had focused 
their studies on elucidating the CD151-integrin binding motif. Zebian S et al, in 2010 
performed mutational analysis of several CD151 domains and found that mutations in the 
LEL completely abolished association between CD151 and integrins, as well as CD151 
with other tetraspanin members. More specifically, alteration of the QRD motif of CD151
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in A431 epithelial carcinoma cells impaired immunoprécipitation with a3(31 under 
stringent conditions. On the other hand, mutation of CD151 palmitoylation sites inhibited 
CD151 association with other tetraspanin members [110]. Subsequent experiments 
showed that the profound negative effect on cell migration as a result CD151 knock­
down was not rescued with CD151 mutated on the LEL, but partially rescued by the use 
of a QRD mutant [110]. CD151 interaction with a3pi, through its QRD sequence has 
been demonstrated in various cell lines such as MDA-MB-231(BCa cells) [109], Cos7 
(monkey kidney cells) and NIH3T3 cells (mouse fibroblasts), among others [111],
To further explore the importance of CD151 in molecular processes, a CD151 -/- mice 
was generated. Deletion of the CD151 gene resulted in viable offspring with only minor 
alterations in immune and blood cell counts and platelet aggregation leading to increased 
bleeding, although no change in integrins a3/6 expression was noted. Noticeably, 
however, cell migration in CD151 null kératinocytes was reduced [112]. In addition, 
reports of CD151 loss in humans and experimental mouse models mention basement 
membrane related defects, including skin blistering and renal failure as well as defects in 
wound healing. Both defects strongly associate with defective cell migration [113].
Several scientists have also utilized CD151 knock down approaches on multiple cell lines 
and animal models to further validate the roles of CD151 in cell migration, invasion, 
angiogenesis, cancer progression and metastasis. For instance, Winterwood et al., in 2006 
silenced CD151 in epidermal carcinoma cells and observed significant reduction in cell 
migration on laminin-5 that was dependent on interaction of CD151 with a3pi, as well as 
a decrease in the degree of endogenous laminin-5 deposition by these mutants when 
compared with wild type cells. In addition, a reduction in migration was observed on 
collagen I and fibronectin. In a different study, Liu et al 2007 proved that reduced
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expression of CD151 lead to diminished internalization of its partners i.e. a3|31 which 
resulted in reduced tumour cell motility on fibronectin and laminin. Competition assays 
also demonstrated that CD151 depletion reduced binding affinity of a3pi to laminin 5 
indicating that CD151 not only stabilized this but also regulated integrin trafficking. This 
clearly implicates that internalization of integrins is required for efficient forward 
migration [10].
1.4.3 CD151 and tetraspanin enriched microdomains: Outside-in signalling
CD151 has been shown to have a role in various steps of cell migration especially during 
cell adhesion. One of the most important characteristics of CD151 is the formation of 
tetraspanin enriched microdomains formed by clusters of tetraspanins that associate with 
growth factors, integrins, tetraspanins, and other many proteins in the cell membrane and 
serve as platforms for the initiation of signalling complexes that result in multiple cellular 
responses [20, 21]. Among these responses are protein trafficking and signalling, platelet 
aggregation [115], cell adhesion [116], cell fusion, and cell morphology, thereby 
influencing immune responses, hematopoiesis, fertilization, cell invasion, cell migration 
[10, 13], and tumour progression and metastasis [9, 11, 12, 117].
To demonstrate the effect that CD151 -growth factor interactions have in the context of 
'cell migration, Sedej et al., 2010 compared colonies formed in 3D matrigel by CD151 + 
and CD151 - MDA-MB-231 cells and found that ~ 80% of the colonies formed by 
CD151 + cells were less compact and the cells exhibited characteristic elongating 
protrusions. It was shown that this colony scattered phenotype was dependent on CD151
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regulation of integrin mediated phosphorylation of p38 in MDA-MB-231 cells in 
response to TGFpi stimulation. In addition to this role, CD151 also regulated the 
compartmentalization of TGF (31 receptor [118]. A similar phenotype was observed when 
HEp3 tumours were treated with a monoclonal antibody specific for CD151. Briefly, after 
injection of HEp3 cells and treatment with mAb 1A5, treated animals developed more 
compact tumours composed of cells that were unable to detach. This illustrates the role of 
CD151 in tumour cell migration and invasion [117]. A different, but related study proved 
that CD151 silencing on malignant breast cancer cells, i.e. MDA-MB-231 and J110, 
significantly decreased cell migration that was dependent on CD151-a6 interaction. This 
was a result of CD151 associated reduction in pFAK and pick. Racl integrin dependent 
activation was also diminished demonstrating the importance of CD151 as an outside-in 
signaling effector.
There is another example of the role of CD151 as a cell membrane effector of 
downstream signalling pathways that results in altered cell migration. In disagreement 
with the multiple studies described elsewhere that show that single cell migration was 
reduced after silencing of CD151, Johnson et al., in 2009 proposed that CD151 also has 
an influence in collective cell migration of intact monolayers. Opposite to most studies, 
they demonstrated that knocking down GDI51 expression exerted a significant 
enhancement in the cell migration rate of these monolayers. This effect was achieved 
through CD151 influence in mislocalization o f E-cadherin, a-catenin, plakoglobin and 
pl20ctn in cell-cell junctions of A431 cells. CD151 participation in the stabilization of 
actin stress fibers was also noted at the basal surface of CD151 mutants. Noticeably, this 
pattern was somewhat disorganized, which was a common feature present in P-catenin
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interactions as well. Levels of activated RhoA were particularly elevated when CD151 
expression was low, explaining at least in part the increase in stress fibers, as well as why 
cell-cell contacts were threefold more active and therefore had shorter lifespan leading to 
the increase in intra-monolayer motility [119].
Additionally, loss of expression of CD151 affects integrin binding dynamics. In the 
absence of CD151, a3pi no longer associated with the member of the Ig superfamily, 
EWI-2, nor it did with the tetraspanins CD81 and CD9, which is indicative of the ability 
of CD151 to form TEMs. Moreover, CD151 silencing induced formation of lateral 
membrane protrusions and changes in directionality. Reduction of a3pi internalization 
was also observed, suggesting that CD151 dependent integrin trafficking to the cytoplasm 
was necessary for proper cell motility. Interestingly, a6 dependent cell adhesion and 
spreading was also disturbed in mutants [120]. The results obtained by this group were 
not surprising since Yanez-Mo M in 1998 demonstrated that CD151 associated with 
CD9, CD81 and a3pi to modulate HUVECs (Human Umbilical Vein Endothelial Cells) 
migration and invasion in Collagen I gels [13, 121]. Furthermore, integrin-tetraspanin 
interaction, more specifically a3pi-CD151 regulated cell adhesion complexes involved in 
cadherin mediated adhesion through gene regulation of protein tyrosine phosphatases 
(PTPp) [122].
1.4.4 The importance of CD151 in cancer
After summarizing the effect of CD151 on cell migration, it is not surprising that CD151 
has been associated with tumourgenicity. In fact, CD151 is frequently up-regulated in
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cancer [20] and its expression is often associated with poor outcome in several cancers. In 
hepatic cancer, for instance, increased mRNA levels and protein expression associated 
with larger tumours, poor differentiation and metastasis. Two and five year survival rates 
were higher for patients with low CD151 expression [123]. In addition, Ke AW et al, in 
2009 showed that high CD151 expression as detected by qrtPCR and IHC associated with
higher metastatic potential. Patients with elevated CD151 expression had multiple larger 
tumours with vascular invasion and had significantly lower overall survival when 
compared with patients with low CD151 expression [14]. Similarly, in lung cancer, 
CD151 positivity, evaluated by rtPCR and IHC, influenced overall five year survival rate 
in adenocarcinoma patients [16]. In the case of clear cell renal carcinoma there was 
significant association between high CD151 staining and pTNM stage, nuclear grade, 
tumour size, age, lung and bone metastasis, in addition to shorter cancer-specific survival 
and progression-free survival [17]. Lastly, but not less important, Susuki S et al, 2011 
demonstrated that CD151 positive expression in esophageal squamous cell carcinoma 
associated with tumour depth, metastasis, increased proliferation and lower five-year 
survival rates [15].
Additionally, Takeda et al, 2011 demonstrated the importance of CD151 in cancer 
metastasis by using CD151 knockout (KO) mice. Briefly, they injected either MLECs 
(mouse lung endothelial cells), B16F10 cells (mouse melanoma) or LLC cells (Lewis 
Lung Carcinoma cells) into CD151 KO mice C57BL/6J and noticed that mice lacking 
CD151 had fewer lung metastasis in an experimental metastasis assay [124],
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Figure 1.6 Participation of CD151 in cell migration pathways. Upon CD151 binding 
with integrins and other proteins to form the TEMs, a series of signalling pathways get 
activated to promote cell migration. Top: schematic of some of the multiple pathways that 
CD151 influences on in terms of locomotion. Bottom: Once the cell gets in contact with 
“clues”, growth factors, cytokines, Ca++, etc., its cell receptors orientate towards the 
signal and the migration steps take place. CD151 is involved in cell adhesion, 
hemidesmosome formation, and retraction of the rear of the cell.
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This reduction was not due to an effect on cell growth, microvascular density, apoptosis 
or differences in leukocyte interaction, but to a reduction in cell adherence of B16F10 
cells to MLECs in KO mice, reduced cell spreading and disorganized laminin ECM. After 
VEGF stimulation, Src, and Akt activation was reduced in KO mice. Additionally, 
transendothelial migration of B16F10s through CD151-null endothelial cells was reduced 
due to a decrease in tumour cell induced endothelial retraction (permeability). These 
results indicate that CD151 also plays a role in endothelial response to VEGF.
Lastly, we have demonstrated the importance of CD151 by showing that CD151-specific 
monoclonal antibody 1A5 (mAb 1A5) prevented metastasis in mouse and chicken 
embryo models by inhibiting tumour cell intravasation without affecting primary tumour 
growth, tumour cell arrest, extravasation, or growth at the secondary site [117]. In vivo, 
this activity, unique to mAb 1A5, results from a strong inhibition of migration due to 
enhanced tumour cell-matrix interactions. Other CD151-specific antibodies promoted 
tumour cell migration [125, 126].
1.5. Clinical relevance of targeting cell migration associated proteins: RHAMM as a 
therapeutic target and CD151 as a prognostic factor in PCa
Most therapies are addressed to kill the primary tumour, but if clinicians want to avoid 
dissemination o f the tumour, they need to treat with aggressive approaches, causing 
innumerable negative side effects on the patients. It is, therefore, necessary to implement 
new, different ways of treatment for these patients. More and more researchers have been 
focussing their studies on finding ways to stop the occurrence of early events of
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metastasis such as cell migration Targeting this event could potentially not only reduce 
the risk of dissemination of cancer cells from the primary tumour to a distant site, but also 
help to prevent local invasion and further dissemination after metastasis has been 
identified.
In theory, approaches that address any step in the metastatic cascade should be a good 
therapeutic target. However, in our lab, we strongly believe that inhibiting the very first 
aspects of metastasis are the best targets since their abrogation translates into a greater 
chance of reduction of disseminatioa Targeting cell migration can stop local invasion and 
metastasis by limiting the disease and therefore reducing mortality and morbidity since 
clinicians may no longer need to provide aggressive treatments to patients at higher risk. 
This endeavour is not easy though. It is necessary to find therapeutics that only disrupt 
pathologic cell migration without affecting normal physiological functioa
The main challenge at the moment in designing any anti migration therapy is the time to 
start it and its duratioa Unfortunately, there are not very many biomarkers for metastasis. 
If one could predict which patients are at higher risk of developing metastasis for each 
type of cancer, the design of a treatment scheme should be easier and perhaps more 
successful.
1.5.1 Therapeutic targeting of the migration-associated protein RHAMM
As discussed above, RHAMM plays a major role in cell migration and tumour 
progression. Moreover, RHAMM upregulation occurs under very specific conditions,
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namely, embryogenesis, wound healing, and cancer. This is very advantageous in terms 
of therapeutic targeting. Since it is not expressed in many tissues during normal 
conditions, one would expect that treatment options targeting RHAMM would be highly 
specific and would not cause major adverse side effects. It is based on this hypothesis that 
a number of scientists have intended to cure different types of malignancies with 
RHAMM based therapies.
Currently, there is a vaccine based on a RHAMM peptide that has been used in a number 
of clinical trials. Specifically, RHAMM R3 peptide has been assessed recently in 
Phasel/II clinical trials for treatment o f AML, MM, and CLL [127-129]. This treatment 
resulted in blast reduction in the bone marrow and leukemic blast lysis and avoided the 
need for blood transfusions for one patient. Also, immunological response, marked by an 
increase in T cell frequency, was observed in 70% of AML, MM, and MDS patients in an 
initial study [129]. In agreement with the above mentioned advantages, treatment with 
RHAMM peptide has yielded very low toxicity because it is not expressed in healthy 
bone marrow tissue. Additionally, vaccination with DC pre-stimulated against the 
previously mentioned peptide has also undergone Phase I/II clinical trials for treatment of 
CLL. Clinical response was correlated with an increase in CD8+ T cell proliferation and 
in some cases a decrease in Treg population. Interestingly, in B-CLL patients with 
clinical response to vaccination with stimulated DC cells, the CD8+ cytotoxic T cell and 
IL-12 anti-tumour response was increased, whereas the Treg cell population was 
decreased [130]. Subsequently, Greiner et al., in 2010 demonstrated that there was no 
dose-dependent effect o f this vaccine, indicating that RHAMM is an effective therapeutic 
target even at low levels [131].
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This treatment strategy has not yet been used for epithelial tumours, however, as 
RHAMM is a prognostic marker for many of them and is overexpressed in many cases 
which currently do not have a specific targeted therapeutic option (e.g. basal subtype of 
BCa) and given the magnitude o f the response, along with such low toxicity, it is an 
approach which merits further consideratioa
1.5.2 Use of CD151 as a prognostic biomarker for disease recurrence and metastasis
As mentioned above CD151is a tetraspanin frequently up-regulated in cancer and has 
been able to predict the outcome of multiple cancers. It is therefore not surprising that a 
number of scientists have proposed the use of mAbs to CD151 and other tetraspanins for 
the treatment o f tumours. Multiple antibodies to CD151 have been designed and used 
throughout the years in vitro and also in vivo in animal models [132]. These recognize 
different epitopes in different tissues in vitro and some are specific for CD151 bound to 
other proteins i.e. integrins and have been able to either inhibit or enhance not only cell 
migration, but also metastasis in animal models [117, 133, 134]. Many of these antibodies 
target sequences present in the LEL of CD151 disrupting with this its interactions with 
integrins and resulting in reduced cell migration (SFA1.2B4) [134], This wasd 
accompanied by altered/enhanced adhesion by gluing the rear of the cell to the primary 
tumour (1 A5)[l 17], increasing homotypic cell attachment which enhances cell-cell 
junctions (11B1.G4) [135], and/or decreasing in invasion and angiogenesis (50-6) [133]. 
Most likely, the effect observed with these antibodies is due to an effect on ligand binding 
that ultimately alters downstream effectors such as reduction in activation o f RhoA, Raf,
32
PI3K, Akt, as well as stabilization of E-cadherin and inhibition of (3-cate nin, among other 
implications.
Even though CD151 has demonstrated to be a good prospective therapeutic target in the 
cancer field, the fact that it is a ubiquitous protein (for reference see CD151 gene in Gene 
note and GNF BioGPS databases) and that the use of these antibodies in humans 
influence for instance platelet aggregation, has made researchers step back on this 
approach. Remaining, though, is its ability to predict the clinical outcome of patients with 
cancer. We strongly believe that the identification of CD151immunoreactivity in the 
initial biopsy tissue can help physicians to determine what patients could benefit from 
more aggressive treatment modalities increasing with this their survival.
1.6 Final note
The intent of this thesis is, by no means, to find an association or interactions between 
these two proteins, but to demonstrate that protein members of different families can have 
similar downstream effects i.e. on cell migratioa Additionally, my goal is to show how 
targeting of proteins involved in cell migration can be of great use in the clinic. Although 
CD151 to date cannot be targeted for therapy because o f the above mentioned pitfalls, it 
indeed can help to predict clinical outcome of several types of cancer. On the other hand, 
RHAMM has been proven to be useful in the clinic as a treatment for blood malignancies; 
although the molecular mechanisms that make RHAMM an oncogenic protein are still 
subject of study.
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Here I describe the utility of CD151 as a prognostic factor in prostate cancer and 
contribute to a better understanding of the Rhamm molecule by showing how one Rhamm 
isoform induces cell transformation through an ERK1,2 related mechanism and localizes 
at different subcellular compartments when compared with the full length form
1.7 Hypotheses
1. CD151 as detected by mAb 1A5 is a molecular prognostic factor for prostate cancer 
disease progression and metastasis.
2. Rhamm FL and Rhamm A163 isoforms have different functions and subcellular 
localization in MEFs and 10Tl/2s.
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The transforming potential of many oncoproteins can be “activated” by alternative gene 
splicing and post-translational modifications. These modifications may expose cryptic 
active sites, remove inhibitory sequences or influence the localization/function of 
oncoproteins. RHAMM is an oncoprotein, tumor marker, and novel breast cancer 
susceptibility gene that belongs to a family of hyaluronan binding proteins defined as 
hyaladherins. It is displayed both inside the cell, where it decorates the mitotic spindle, 
and outside the cell where it binds to receptors such as CD44 and growth factor receptors. 
RHAMM is subject to alternative splicing and post-translational modification and both of 
these processes are thought to affect its subcellular compartmentalization. Furthermore, 
some of these modifications have been associated with aggressive tumour behaviour.
Here we demonstrate that RHAMMFL can be “activated” into a transforming form by the 
removal of its N-terminal 163 amino acids, as demonstrated by foci formation and 
anchorage independent growth. These oncogenic effects require MEK1/ERK1,2 activity. 
To assess if this change in function of activated RHAMM is associated with altered 
subcellular compartmentalization, we transiently expressed ZsGreen -RhammFL-FLAG 
and A163 in RHAMM -/- MEFs. Both forms were observed at the cell surface and on 
mitotic spindles as assessed by confocal microscopy. However, in interphase cells, 
intracellular RHAMMFL appears primarily fibrillar and associates with microtubules. On 
the cell surface, RHAMMFL is present as an amorphous coat on the end of cell processes. 
In contrast, intracellular, oncogenic RHAMMa163 is diffuse and is present in several 
compartments in interphase cells, including the nucleus and vesicular structures. 
RHAMMa163 also localizes to podosomes, which are structures required for cell motility
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and invasion. Mass spectrometric analysis of RHAMMFL and Al“ -interacting proteins 
show that both associate with components of the cytoskeleton. RHAMMFL binds more 
robustly to TPM2, tubulin, vimentin, actin and myosin light chains, consistent with its 
observed association with the fibrillar cytoskeleton. Furthermore, FRAP analysis 
suggests that RHAMMFL is less mobile than RHAMMa163. Since the oncogenic 
functions of RHAMMa163 require ERK1,2 activity, the co-association of these MAPK 
with both RHAMM forms was compared using confocal and immunoprécipitation assays. 
In RHAMM -/- MEF and 10T1/2 cells, both RHAMM forms associate with total and 
phospho-ERKl,2, but the interaction is greater with RHAMMa163 than RHAMMFL. 
Furthermore, RHAMM is required for transformation by H-Ras and mutant active MEK1. 
In a reciprocal relationship, RHAMM requires both Ras and MEK1 expression for 
oncogenic activity. These results are consistent with previous experimental data showing 
that RHAMM acts at two locations on a RAS-ERK1,2 pathway: as a cell surface co­
receptor for HA-CD44 interactions, which activate ERK1,2 at the cell membrane, and as 
part of a protein complex with MEK1 and ERK1,2. RHAMMa163 expression promotes 
nuclear accumulation of p-ERKl,2. These results suggest that intracellular RHAMM 
may act as a scaffold for translocating pMEKl, pERKl,2 to the cell nucleus and that this 
property is required for its transformation activity.
2.2 Introduction
It is becoming apparent that many proteins are multifunctional and that this is in part 
affected by their subcellular localization. Specialized targeting sequences that guide and
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dock proteins to specific intracellular and extracellular sites are modulated by alternative 
splicing and post-translational modifications. One well-studied example of this 
mechanism is the signal peptide, which targets proteins to the Golgi-ER and leads to their 
export into the extracellular compartment. Until recently, this paradigm was thought to 
be the only means of secretion but this has recently been challenged [1,2] by evidence 
that a growing group of proteins lacking classical export signal sequences are found on 
the surface of the cell. Examples include epimorphin/syntaxin 2 [2, 3], bFGFl,2 [1] and 
RHAMM/HMMR [4]. These proteins are not exported through golgi/ER but by 
independent routes in response to cell stress such as tissue injury and neoplastic 
transformation. The unconventional export mechanisms involve exocytosis, membrane 
blebbing, transport through the endolysosomal pathway, export via channel proteins and 
export complexes that “flip” the protein across the membrane [4], Importantly, proteins 
that are unconventionally exported to the cell surface often perform distinct functions in 
each compartment. For example, epimorphin is involved in mammary gland 
morphogenesis when expressed outside the cell and a vesicle protein (also called syntaxin 
2) involved in endocytosis when inside the cell [2-4], Similarly, the precise intracellular 
compartmentalization of proteins also affects their function. For example, whether or not 
a protein is oncogenic can depend upon its ability to enter specific subcellular 
compartments. Src requires access to focal adhesions in order to transform cells [5] while 
p-ERK must gain access to the cell nucleus to exert its oncogenic effects [6, 7]. In fact, 
more than 60% of ERK1,2 targets are located in the nucleus, indicating that ERK 
translocation to the nucleus of the cell is required for its function [8].
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Based on this, it is clear that products of single genes can have opposing functions, even 
during oncogenesis. For example, CD44, a hyaluronan receptor that is expressed as 
multiple isoforms [9] resulting from alternative mRNA splicing can both promote tumor 
progression, as is the case of CD44 v6, in colorectal cancer [10] or act as a tumor 
suppressor, CD44-S [11]. Furthermore, CD44-S, the best characterized isoform, has been 
identified as a tumour suppressor in prostate cancer [12] and its loss predicts poor 
outcome in this disease [13, 14]. These differentially expressed isoforms vary in their 
subcellular distribution, association with the matrix, function and their contribution to 
tumour progression [15].
RHAMM is typically expressed after injury, but is also upregulated in many 
inflammatory diseases including arthritis, diabetes and cancer. It belongs to the 
hyaladherin family of hyaluronan binding proteins and is a multifunctional protein that is 
present in both the intracellular and extracellular compartments. A wide variety of cell 
types express RHAMM; including fibroblasts, immune cells, smooth muscle cells, 
endothelial cells, sperm and keratinocytes in culture [16-21]. Intracellular RHAMM 
decorates interphase microtubules, centrosomes and mitotic spindles, but it is also 
diffusely localized throughout the cytoplasm [22-26]. It also localizes to podosomes, 
filopodia and other membrane protrusions [25, 27, 28]. RHAMM is exported to the cell 
surface after wounding {in vivo and in vitro) or at subconfluent levels after stimulation 
with growth factors [28, 29]. On the cell surface, RHAMM interacts with HA and 
complexes with transmembrane receptors such as CD44 [30], PDGFR [31], RON [32], 
and integrins [33]. It promotes the activation of signalling cascades through these 
receptors. For example, RHAMM/CD44 interactions promote maximal activation of
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ERK1,2. RHAMM likely acts as a co-receptor in this activation since it does not have a 
membrane spanning sequence [34].
RHAMM is expressed as both alternatively spliced and post-translationally modified 
proteins [22, 35, 36]. Isoforms that are shorter than the full length protein are transiently 
expressed following injury [37, 38] and constitutively expressed upon neoplastic 
transformation [39]. One o f these, RHAMMa163 is highly expressed in H-Ras transformed 
fibroblasts and its HA binding ability is required for H-Ras to sustain fibroblast 
transformation [39]. There is also clinical evidence to support an oncogenic role for 
RHAMM. RHAMM is elevated in most types of cancer and its over-expression has been 
associated with poor outcome and onset of metastasis in glioma [40], breast [24, 41], 
endometrial [42], colorectal [43, 44], stomach [45], prostate cancer [46], multiple 
myeloma [35] and AML [47]. However, the oncogenic effects of RHAMM isoforms 
other than RHAMMa163 have not been reported. Several studies suggest that RHAMM 
isoforms differ in their distribution. For example, cell surface protein biotinylation 
experiments suggest that only a 70 kDa protein, the size of RHAMMa163, is exported to 
the cell surface [38]. The alternatively spliced RHAMMAe,iDn4 exhibits reduced 
association with interphase microtubules compared to the full length protein and 
selectively traffics to the cell nucleus [22, 26].
Here, we assessed the oncogenicity of truncated RHAMM proteins that are highly 
expressed in aggressive human breast cancer cell lines [34]. We related the differences in 
transformation ability to the distinct subcellular localization of these RHAMM isoforms. 
To assess this, we utilized the 10T1/2 model of cellular transformation and assayed foci 
formation and growth in soft agar. We show that only RHAMMa163 is transforming in
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this model. To unambiguously identify the subcellular distribution o f each RHAMM 
isoform, we transiently expressed recombinant ZsGreen-RHAMM fusion proteins in 
RHAMM -/- MEFs. We show that RHAMMFL, which is not transforming, is associated 
with microtubules while RHAMMa163 is significantly more mobile within the cell and is 
present in many subcellular compartments including the cell nucleus.
2.3 Methods 
Cell culture
Rhamm knockout (-/-) Mouse Embryonic Fibroblasts (MEFs) were isolated as described 
by Tolg et al., 2003 and 2006 [48, 49] and grown as monolayers in low glucose 
Dulbecco’s Modified Eagle’s Medium (DMEM) (Multicell) supplemented with 10% FBS 
(Multicell) and lOmM HEPES (Multicell) at pH 7.2 at 37°C in a humidified 5% CO2 
atmosphere. C3H/10T1/2, mouse fibroblasts were purchased from ATCC (Manassas, VA) 
and maintained under the same conditions as MEFs.
Antibodies
The following antibodies were used in this study: a tubulin rat mAb (Abeam), p tubulin 
mouse mAb (SIGMA), FLAG Tag M2 mouse mAb (SIGMA), FLAG M2 agarose beads 
from mouse (SIGMA) (a kind gift from Dr. Joe Mymryk’s lab), ERK1 and MEK1 (Santa 
Cruz Biotechnology, Inc.), ERK1,2 rabbit polyclonal #9102 (a kind gift from Dr. 
Dimattia’s lab (Cell Signaling), phosphorylated ERK1,2 rabbit polyclonal #4370 (Cell
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Signaling), ZsGreen rabbit polyclonal (Clontech), Rhamm mouse mAb 6B7B7 (Promab), 
Rhamm polyclonal antibody against the sequence QLRQQDEDFR (aa 543-553), non- 
immune IgG (Chemicom) was used as negative control, and species specific IgG + Alexa 
Fluor secondary antibodies (Invitrogen).
Recombinant Rhamm protein constructs
ZsGreen was amplified using the following primers (SIGMA) 5’ EcoRI-ZsGreen 
(AAAAAA GAATTC ATG GCCCAGTCCAAGCACGG) and 3’ 10 first N-terminal 
base pairs of RhammFL/A163- ZsGreen C-teminus (FL: TAGGAAAGGA 
GGGCAAGGCGGAGCCGG and A163: TTAGAGCTCT GGGCAAGGCGGAGCCGG) 
by using the Phusion high fidelity PCR kit (NEB) and following the manufacturer 
recommended conditions. RhammFL and RhammA163 were amplified by PCR using 5’ 10 
last C-terminal base pairs of ZsGreen and the first 16-17 base pairs of the N-terminus of 
Rhamm (FL: CGCCTTGCCC TCCTTTCCTAAGGCGCC and A163: CGCCTTGCCC 
AGAGCTCTAAGCCTGG), and 3’ last 17 C-terminal base pairs of Rhamm-FLAG tag- 
Xhol (AAAAAA CTCGAG TCA CTTGTCATCGTCGTCCTTGTAGTC 
GCAGCAGTTTGGGTTGC). Afterwards, the product of the ZsGreen reaction was 
PCRed with the product of either RhammFL or RhammA163 to allow for annealing of the 
two sequences. After purification (Bio Basic Inc. Gel extraction and PCR product 
purification kits) and enzymatic digestion with EcoRI and Xhol (NEB), the construct was 
ligated into pCDNA 3.1+ plasmid under the control of the CMV promoter, sequenced, 
and transiently expressed into i) Rhamm -/- MEFs, ii) RhammFL rescued Rhamm -/-
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MEFs, iii) RhammA163 rescued Rhamm -/- MEFs, iv) 10Tl/2s, and v) Rhamm -/- 
transfected with mutant active MEK. A plasmid containing only the ZsGreen sequence 
was used as negative control.
Untagged RhammFtyA163 cDNAs were inserted into the pHApr-l-neo expression vector 
under the control of a P-Actin promoter as previously described by Zhang et al., 1998. 
The mutant active MEK and dominant negative MEK1 constructs were kind gifts from 
Dr. Natalie Ahn. Mutant active Ras (H-Ras) and dominant negative H-Ras cDNA (DN- 
RasN17) were kindly provided by Dr. Charming J. Der.
A dominant negative RhammA163 with an N-terminal Leucine zipper mutation was created 
previously in our lab by altering the Hyaluronan Binding Domain (HABD) that overlaps 
withERK D-docking motif. The following substitutions were made, K748N, R749N, and 
K750W.
Rhamm expression in MEFs and 10T1/2 cells
ZsGreen-RhammFI7A163 and ZsGreen only constructs were expressed into the cells by 
transient transfection using jetPRIME (Polyplus transfection reagent). Immortalized 
Rhamm -/- MEFs or 10Tl/2s were grown in monolayers to a confluency of 80-90% in 
DMEM supplemented with 10% FBS for 24 hours. The plasmids were then incubated 
with the transfection reagent as recommended by the manufacturer and added to the cells 
in a ratio of lpg of DNA : 2pL of transfection reagent, brought back to incubation for 12 
hours, and treated according to the experiment needed.
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10Tl/2s were transfected with untagged RhammFL, RhammA163, RhammA163' HABD, H-Ras, 
dominant negative H-Ras, or mutant active MEK 1 using Lipofectamine Plus (Invitrogen)
g /
as described previously [31] stably expressing cells were established by selecting with 1 - 
5mg/mL G418 (SIGMA).
Rhamm -/- MEFs were infected using a retroviral system for expression of untagged 
RhammFL/A163, as described by Tolg et al., 2003 [49] and stable transfectants were 
selected with l-5mg/mL G418 (SIGMA selected using l-5mg/mL G418 (SIGMA).
Western Blot analysis
12 hours after transfection, Rhamm -/- ZsGreen-RhammFIVA163 cells were rinsed twice 
with PBS, detached from the dish with a cell scraper, centrifuged at 1400 rpm for 4 
minutes and then lysed withNP40 lysis buffer (1% NP-40, 50mM Tris-HCl, pH 8.0, 150 
mM NaCl) containing protease inhibitor cocktail. Protein was collected and concentration 
was measured by the Bradford protein assay (BioRad). 30pg of protein was loaded onto 
8% gels, separated using SDS-PAGE, and transferred to a PVDF membrane (GE 
Healthcare). Then, the membrane was rinsed with TBST (lOmM Tris base pH 7.4, 
150mM NaCl, and 0.1% Tween-20) and blocked for an hour at room temperature in 5% 
skim milk in TBST. Subsequently, the membranes were incubated with rabbit pAb to 
ZsGreen (1:1000) or mouse mAb to FLAG tag (1:5000) in 5% skim milk in TBST 
overnight at 4°C. After several washes with TBST, horseradish peroxidase conjugated 
secondary antibody (1:10,000 in 5% skim milk in TBST) incubation was performed for 
one hour at room temperature followed by several washes with TBST. The presence of
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protein was evidenced by using the enhanced chemiluminescence (ECL) detection kit 
(GE Healthcare).
Cell lysates from 10T1/2 cells were isolated with RIPA buffer (25mM Tris-HCl pH 7.2, 
0.1% SDS, 1% Triton X-100, 1% Sodium deoxycholate, 0.15M NaCl, ImM EDTA, and 
50mM HEPES pH7.3) containing protease and phosphatase inhibitor cocktails on ice. 
Lysates were then incubated on ice for 20 minutes and then were centrifuged for 20 
minutes at 13,000 x g at 4°C. Protein concentration was determined using the DC protein 
assay (Bio-Rad). Nuclear extracts were prepared following the manufacturer’s 
instructions (Nuclear Extract kit, Active Motif). 10-50pg of protein were electrophoresed 
on a 10% SDS-PAGE gel and transferred to nitrocellulose membranes (Bio-Rad). 
Nonspecific binding was blocked with 3% skim milk in TBST at 4°C. Primary and 
secondary antibodies were incubated in 1% skim milk in TBST for 1 hour at room 
temperature. Signal was developed with the ECL detection system (Amersham).
Foci formation and colony formation in soft agar
After 10T1/2 cells were stably transfected with H-Ras, dominant negative H-Ras,
RhammFL, RhammA163, mutant RhammA163' HABD', or empty vector using Lipofectamine 
Plus as described above, foci formation was assessed as follows. Post-transfected cells 
were grown in DMEM supplemented with 10% FBS during 10-15 days at 37°C with 5% 
C02. Then, cells were fixed with 4% formaldehyde for 10 minutes at room temperature 
and stained with methylene blue as described by Zhang et al., in 1998 [31]. The number
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and size of foci were analysed and then normalized according to transfection efficiency 
measured by western blot. All experiments were performed in triplicate.
Colony formation in soft agar was measured by suspending lxlO5 transfected 10T1/2 
cells in 0.3% agarose in 4mL of DMEM supplemented with 10% FBS. The cells were 
plated onto a 60mm petri dishes pre-coated with 0.8% agarose in DMEM 10% FBS. The 
cells were then incubated for 15-20 days at 37°C with 5% C02 The number of colonies 
was quantified and normalized according to transfection efficiency measured by western 
blot. All experiments were performed in triplicate.
Immunofluorescence staining and co-localization analysis
After transfection, the cells were seeded onto glass coverslips at a confluency of 50-60% 
and allowed to attach for 7-8 hours. The cells were then washed and fixed with 4% 
formaldehyde solution in PBS for 10 minutes at room temperature. After 2-3 washes with 
PBS, the cells were incubated one hour at room temperature with PBS- 1% BSA with or 
without 0.1% Triton X-100 (BioShop) depending on the need for intact membranes. For 
pERK staining, TBS was used instead of PBS. Subsequently, the cells were incubated 
with primary antibodies (Anti a tubulin, |3 tubulin, FLAG, pERK 1:1000) overnight at 
4°C followed by several washes with PBS/TBS and incubation with species specific 
Alexa Fluor conjugated secondary antibodies (1:2000) (Invitrogen) for one hour at room 
temperature. Non-immune IgG was used as negative control. After rinsing, the coverslips 
were then mounted using Prolong Gold DAPI antifade reagent (Invitrogen) and imaged.
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Confocal images were taken using an oil 63x/60x objective in either a spinning-disk 
confocal microscope, using a specialized instrument (Quorum Technologies, Guelph, ON, 
Canada) comprised of an upright Zeiss Axio Examiner Zl, LUDL filter wheels and large 
format motorized stage, a Yokogawa spinning disk head and a Hamamatsu 9100-12 
Image EM CCD camera, controlled by Volocity (Improvision, UK) or an Olympus Fluo 
View ™ FV1000 coupled to the 1X81 Motorized Inverted laser scanning confocal 
microscope LX2 series. For co-localization analysis, images were acquired at 60-63x 
magnification with oil objectives and 24 regions of interest were selected in a total of 6 
cells per group and Pearsons correlation was performed by the software Volocity after 
establishing background threshold.
Fluorescence recovery after photobleaching and confocal imaging
After transfection, cells were plated in chambered coverglass plates (Lab-Tek) with 
phenol red free DMEM (Multicell) 10% FBS, 0.2% HEPES and allowed to attach for 7-8 
hours. FRAP was performed with the Olympus inverted laser scanning confocal 
microscope LX2 series enclosed in a temperature controlled chamber. Briefly, a region of 
interest (ROI) o f 45 pm2 was delineated and fluorescence of ZsGreen-RhammF 17A163 was 
measured before and after photobleaching. Four images were taken before 
photobleaching and the ROI were then exposed to a circular tornado scan with a 488nm 
laser at 100% power. 120 images at intervals of 2.5 seconds were acquired with a 60x oil 
objective after exposure was performed. A total of 6 cells were analysed per group and 
initial fluorescence intensity was normalized to 1. Measurement of fluorescence intensity
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before and after photobleaching was performed at 120 timepoints. Then, fluorescence 
recovery was plotted against timepoints and non-linear curve fitting was carried out by 
the software FV 10-ASW 1.6.
Immunoprécipitation assays
12 hours after transfection of Rhamm -/- MEFs with ZsGreen-RhammFUA163, the cells 
were serum starved for 12 hours and then stimulated with 10% FBS for 10-15 minutes. 
Immediately after the cells were removed from the plate with a cell scraper, centrifuged at 
4°C, the pellet was rinsed three times with PBS and lysed with F buffer (Described by 
Michael Cole’s laboratory: lOmM TRIS pH7.5, 50mM NaCl, 30mM Sodium 
Pyrophosphate, 50mM Sodium Fluoride, 5pM ZnCl2, and 0.5% Triton X-100; (a kind gift 
from Dr. Joe Mymryk’s lab) with protease inhibitor cocktail and ImM Orthovanadate for 
five minutes on ice. The lysates were then centrifuged at 13500rpm for 10 minutes at 4°C. 
Subsequently, the protein solution was incubated with mouse anti-FLAG M2 agarose 
(SIGMA) (another kind gift from Dr. Joe Mymryk’s lab) overnight at 4°C. After 
centrifuging the pellet was rinsed 5 times with F buffer and resuspended in SDS-DTT 
loading dye. SDS-PAGE and protein transfer was performed as described above and 
probed with ERK1/2 and pERKl/2 rabbit polyclonal antibodies. Cell lysates/input were 
also tested following the same procedure.
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Mass Spectrometiy analysis of proteins
Recombinant GST-RHAMMFL and RHAMMa163 were prepared as described previously
[50] and linked to Glutathione-linked beads. Cell monolayers were grown to culture 
confluence and solubilised in RIPA buffer. A cell scraper was used to remove all of the 
cellular debris and extracellular material from the culture dish. The solubilised and 
scraped material was mixed using a vortex then the pellet was prepared by centrifugation. 
The supernatant was discarded and the pellet was solubilised using a modified RIPA 
buffer and vortexing. The pellet contained primarily cytoskeleton proteins as judged by 
Mass Spec analysis. Recombinant RHAMM-beads were mixed with the solubilised cell 
pellet overnight at 4°C, beads were washed and then proteins that were bound to 
RHAMM were released using lOmM glutathione. Released proteins were separated by 
SDS-PAGE (7-14% gradient gels) and lightly stained with silver to identify protein 
bands. Bands that were clearly separated from one another were cut out and analysed by 
MALDI-TOFF (Proteomics Research Center, University of Toronto).
Statistical analysis
Differences between multiple groups were measured using One-way ANOVA and 
Tukey’s comparison post-test. Statistical differences between two groups were assessed 




RhammA163 induces growth transformation in 10T1/2 fibroblasts
Our first aim was to test if  overexpression of RhammA163 confers the cells with the ability 
to proliferate independently of both inhibitory signals, such as the absence of a solid 
substratum, and regardless of growth contact inhibition signals. For this, the transforming 
potential of the truncated Rhamm protein forms shown in Figure 2.1 A was assessed in 
two separate assays: i. foci formation and ii. growth in soft agar. H-Ras transformed 
10T1/2 fibroblasts were used as positive controls for these assays. RhammA163 was found 
to be transforming in 10T1/2 cells. As shown in Figure 2.IB, both H-Ras and RhammA163 
transfected 10T1/2 cells formed foci after 10-15 days of incubation, but empty vector 
transfected and RhammFL transfected 10T1/2 fibroblasts did not. The ability of these 
transfectants to form colonies in soft agar, which is a measure of resistance to anoikis, 
was also measured (Fig. 2 .ID). Both H-Ras and RhammA163 formed abundant colonies in 
this assay. RhammFL, formed fewer colonies than either RhammA163 or H-Ras expressing 
cells but more than empty vector transfected cells. These results suggest that expression 
of either Rhamm isoform provides some protection against anoikis.
RhammA163 acts at the level of Ras and MEK1 to promote growth transformation in 
10T1/2 cells
We and others have previously shown that Rhamm acts through the Ras pathway to 
control cell migration and transformation [51]. Since Ras influences multiple pathways,
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we next determined through which RAS effectors RhammA163 mediates signalling. Since 
Rhamm/HA or growth factor interactions can activate ERK1,2, we assessed if 
RhammA163/ ERK1,2 interactions were required for this process.
For this purpose a mutant inactive version of RhammA163 was created by site directed 
mutagenesis in the overlapping HA and ERK binding sites of RhammAI63 (illustrated in 
figure 2.1 A). We first co-transfected 10T1/2 fibroblasts with a plasmid containing H-Ras 
and with the mutant inactive RhammA163 HABD” sequence; an empty vector was used a 
negative control. Foci formation was reduced in about 50% in the cells transfected with 
the RhammA163 HABI> cDNA when compared with those transfected with H-Ras + empty 
vector (Figure 2.2A) indicating that RhammA163 is acting upstream of Ras. In a different 
but related experiment, RhammAI63 and mutant inactive H-Ras cDNA <DN-RasN17) were 
transfected in 10T1/2 cells and the ability o f the cells to form foci was assessed. The 
effect of RhammA163 on contact inhibition of cell growth was reduced by approximately 
60% after co-expression of the Ras mutant indicating a role of RhammA163 upstream of 
Ras in this process (Figure 2.2 B).
To dissect, in more detail, the downstream effects of RhammAI63, we developed a model 
in which we transfected simultaneously RhammA163 with a dominant negative MEK1 
cDNA and observed that inhibition of MEK/ERK1,2 activation had a statistically 
significant negative effect on RhammA163 dependent foci formation (Figure 2.2 B). 
Moreover, co-transfection of 10T1/2 cells with a constitutively active MEK1 and mutant 
RhammAI63 HABD~ reduced foci formation by more than 50% (Figure 2.2C). These results 
indicate that Rhamm/ERK1,2 interaction is required for the transforming effect of MEK1 
(Figure 2.3).
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Figure 2.1 RhammA163 transforms growth patterns in 10T1/2 fibroblasts. Colony 
growth in soft agar and foci formation was assessed in H-ras transformed 10T1/2 
fibroblasts overexpressing RhammhL and RhammAI63. A) Schematic of Rhamm isoforms. 
RhammH' possesses two tubulin binding sites (leucine zippers represented as red squares), 
two HA binding sites at the C-terminal sequence (illustrated in purple squares) and a D- 
domain ERK binding site on residues 748-756 of the protein (yellow square). RhammAlft3 
isoform lacks the N-terminal tubulin binding site and RhammAI63 HABD" was mutated by 
site directed mutagenesis in the D-domain and HA binding site as indicated. B) 
RhammA163 promotes foci formation when overexpressed in 10Tl/2s. Quantification of 
foci formation is represented in C. D) Representative image of colony formation in soft 
agar of 10T1/2 after transfection with either RhammF L or RhammAI63. H-Ras transformed 
fibroblasts were used as positive control, both experiments were performed in triplicate, 
and the results were normalized to the expression levels as assessed by western blot 
analysis after transient transfection.
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Figure 2.2 RhammA163 acts upstream of Ras and at the level of ERK to promote 
growth transformation. Mutant RhammA163 HABD_, inactive Ras (DN-RasN17), and 
double negative MEK1 (DN MEK1) were transfected in 10T1/2 fibroblasts and their 
effect in foci formation was assessed. 10T1/2 cells were transfected with: A) H-Ras and 
RhammA163 HABD_ 5 B) Rhamm A163 and either inactive Ras or inactive MEK1, or C) 
Mutant active MEK1 and RhammA163 HABD‘ and foci formation was measured. The 
relative number of foci was arbitrarily set to 100 and the data was then normalized to the 
positive control in each experiment. The experiments were performed in triplicate. * p < 
0.05
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Figure 2.3 Proposed mechanisms for RhammAIW transforming effects. Rhamm 
upstream of Ras and at the level of ERK1,2 to induce cell transformation. Additionally, 
RhammAI63 induces pERK translocation to the nucleus of the cell and mediates its 
sustained expression there. This may influence Rhamm associated oncogenicity.
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Subcellular localization of ZsGreen-Rhamm isoforms in MEFs
To assess if the transforming effect of RhammA163 is associated with altered subcellular 
compartmentalization, and to observe the subcellular localization of different Rhamm 
isoforms, we prepared ZsGreen-FLA G-Rhamm1 L and A163 constructs (Figure 2.4A and B) 
then transiently expressed these in Rhamm -/- MEFs. Figure 2.4C demonstrates similar 
transfection efficiency for both isoforms and the ability of the FLAG and ZsGreen 
antibodies to detect the expressed proteins in Rhamm -/- MEFs. Confocal analysis 
suggested that both forms localize to mitotic spindles during mitosis (Figure 2.5A). In 
addition, staining using a ZsGreen antibody in cells that were not previously 
permeabilized suggests the presence of both isoforms of Rhamm at the cell surface 
(Figure 2.5B). However, during interphase, intracellular Rhamm1 L appears primarily 
fibrillar, whereas on the cell surface RhammFL is present as an amorphous coat on the end 
of cell processes. In contrast, the intracellular pool of RhammA1(’3 is diffuse throughout 
the cytoplasm and localizes to several compartments in interphase cells, including the 
nucleus and vesicles (Figure 2.5A). Additionally, Rhamm3163 seems organized within 
podosome-like structures, which are structures required for cell motility and invasion. 
The present results indicate not only that Rhamm isoforms have different subcellular 
distribution, but also that having attached a fluorescent protein on the N-terminus and a 
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Figure 2.4 ZsGreen-RhammH j/A163 constructs. ZsGreen-Rhamm1 LAI63 sequences were 
amplified and fused by PCR and inserted into pcDNA 3.1+. A FLAG tag was also 
inserted at the C-terminus of Rhamm (A and B). C) Western blots using ZsGreen and 
FLAG antibodies to assess expression of ZsG-Rhamm in MEFs after transfection 
demonstrate comparable transfection efficiency for both constructs.
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RhammA163 motile/dynamic within the cell
To determine if the different subcellular distribution of Rhamm isoforms are related to the 
motility of these proteins within the cell, we performed fluorescence recovery after 
photobleaching (FRAP) analysis of our constructs in transiently transfected MEFs. 
Rhamm surface diffusion velocity reflects the state of the labelled protein in that unbound 
protein diffuses faster than bound protein. We found that ZsGreen-RhammFL exhibited a 
significantly lower recovery rate than its counterpart, ZsGreen-RhammA163 (p<0.0009) 
(Figure 2.6). This suggests that a pool of RhammFLis stably associated with rigid cellular 
structures, which would reduce its ability to diffuse through the cell cytoplasm.
Rhamm associates with cytoskeletal proteins
Rhamm has been previously described as a tubulin/actin binding protein [20, 22, 26, 34, 
48, 52], Based on Rhamm"' distribution and motility in the cytoplasm, we hypothesized 
that this isoform has higher binding affinity for cytoskeletal proteins. To test this, we 
transfected Rhamm"' or Rhamm3163 into 10T1/2 cells, performed a pull-down and 
analysed the proteins that attached to Rhamm using matrix-assisted laser desorption 
ionization time-of-flight (MALDI TOF) mass spectroscopy (MS). In general, Rhamm1 L 
seems to preferentially bind to cytoskeletal proteins when compared to RhammAlt” 
(Figure 2.7 A). These results suggest that both isoforms of Rhamm bind to actin and 
tubulin, and to other actin scaffold proteins such as Filamin a (FLNA), Spectrin a 
erythrocytic 1 (SPTA1), and Spectrin P non-erythrocytic 4 (SPNB4).
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Figure 2.5 Distribution of the Rhamm constructs in the cell. Confocal images of 
MEFs transfected with either ZsGreen-RhammFL or RhammAI63 illustrate differences in 
the distribution of Rhamm isoforms in the cytoplasm (A). RhammFL is expressed in fibre- 
like structures whereas RhammA163 is diffuse in the cytoplasm. Both isoforms translocate 
to the nuclei of MEFs during mitosis where they decorate the mitotic spindle. B) 
Immunofluorescence staining of MEFs transfected with ZsGreen-Rhamm using a 
ZsGreen antibody (red) detects the presence of ZsGreen-Rhamm fusion in the membrane 
of the cells. The cells were stained in the absence of membrane permeabilization or 
detergent. Scale bars, 20pm.
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However, Rhamm1 L seemed to associate to a higher degree with smooth muscle actin 2 
(ACTA2), Vimentin (VIM), Tubulin (34 (TUBB4), Tropomyosin 2 (TPMS2), and Myosin 
(My 1,4,6, and 6B) than RhammAI63 (Table 2.1 ).
Furthermore, co-localization analysis performed on MEFs demonstrated that ZsGreen- 
RhammFI more strongly co-localized with a  and P tubulin than ZsGreen-RhammAI6’ 
(pO.OOOl) (Figure 2.7 B). ZsGreen alone was used as negative control and did not show 
co-localization with tubulin.
Rhamm immunoprecipitates with ERK1/2 and co-localizes with pERKl/2 in MEFs
Since the oncogenic functions of RHAMMa163 require ERK1,2 activity, the co­
association of both Rhamm forms with ERK1,2 was compared using confocal and 
immunoprécipitation assays. After transient transfection of our constructs into Rhamm -/- 
MEFs and staining with pERKl,2 antibody, Pearsons correlation of co-localization of our 
constructs with pERK demonstrated that there is a modest degree of co-distribution 
between both isoforms and activated ERK1,2. The range of co-localization was slight 
although significantly more pronounced in the cells transfected with ZsGreen-RhammA163 
(p<0.009) when compared with ZsGreen-RhammFL. No association was found between 
pERK and MEFs transfected with ZsGreen (Figure 2.8 A). Additionally, we assessed for 
interactions between the above mentioned proteins by immunoprécipitation assays and 
observed that both isoforms of Rhamm in these constructs associated with ERK 1,2. The 
same effect was not noticed when cells containing the plasmid with ZsGreen alone were 
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Figure 2.6 Rhamm isoforms have different motility/dynamics in the cytoplasm of 
MEFs. Fluorescence Recovery After Photobleaching (FRAP) analysis was performed in 
Rhamm -/- MEFs transiently transfected with ZsGreen-RhammHMI63 constructs. 
ZsGreen-Rhamm'163 was more mobile than ZsGreen-RhammFL. A total of 6 cells were 
analysed per group. Mean normalized fluorescence recovery was plotted against 
timepoints. Each line in the graph represents the mean recovery rate of one group 
(±SEM). Scale bar, 20pm
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RhammUi’3 induces ERK1,2 trafficking and phosphorylation
We have demonstrated thus far that Rhamm/ERK1,2 interactions are required for growth 
transformation, and previous studies have shown that ERK1,2 translocation to the nucleus 
of the cell is required for cell transformation [6, 7], Thus, we hypothesized that 
RhammAI6j plays a role in this process. To investigate this further, we looked for 
differences in ERK levels between Rhamm -/- MEFs and Rhamm -/- transfected with 
RhammAlb3. The levels of pERKl,2 in the nuclei and in the membrane of our MEFs were 
higher after serum stimulation. These high levels were also sustained in the cells 
expressing RhammAi<" over a period of 24 hours as detected by immunofluorescence 
staining (Figure 2.9 A). Additionally, Western blot analysis of pERKl,2 after nuclear 
extraction in 10T1/2 cells demonstrated that the over-expression of the N-terminal 
truncated RhammAI63 induced the translocation of pERKl,2 to the nucleus which 
persisted for at least 60 minutes post-stimulation with FBS (Figure 2.9 B). In addition, 
when a nuclear export signal (NES) was added to the MEK1 sequence to reduce the 
levels of active MEK/ERK in the nuclei of LR21 cells (Clonal population of 10T1/2 
mouse fibroblasts transfected with RhammAlb3), a significant reduction in tumour 
formation after injection in NOD SCID mice was observed (P< 0.0005) (data not shown), 
suggesting that the role played by RhammA163 in cellular transformation is at least 
partially due to its ability to activate and induce enhanced and retained nuclear trafficking 
of ERK1,2. Moreover, the presence of pERKl,2 in the membrane of the cell (Figure 
2.4B) indicates that there is an interplay between differentially localized RhammAlbJ.
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Table 2.1 Rhamm binding proteins. After transfection of 10T1/2 fibroblasts with 
RhammFL/A163, pull-down with recombinant Rhamm was performed and mass 
spectrometry-MALDI TOF analysis was performed comparing protein interactions 





One way ANOVA-Tukey’s test ***p<0.009, n: 24
Figure 2.7 Rhamm associates with cytoskeletal proteins. Confocal imaging and 
Pearsons correlation of Rhamm KO MEFs transfected with ZsG-RhammFL Al63 fusion 
and stained using mAbs to a and (3 tubulin (red). For analysis, four regions of interest 
were delineated per cell on a total of 6 cells per group. One way ANOVA with Tukey’s 
post test were used to assess statistical significance. Scale bars, 20pm
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Figure 2.8 Rhamm associates with ERK. A) Confocal imaging and Pearsons correlation 
of Rhamm KO MEFs transfected with ZsG-RhammFL Al63 fusion and stained using pAb 
to pERK evidenced that zsGreen-RhammAI63 fusion co-localizes more with pERK (Red). 
For analysis, four regions of interest were delineated per cell on a total of 6 cells per 
group. B) Immunoprécipitation was performed by using agarose beads coated with FLAG 
mAb to pull down ZsGreen-RFlAMMFl7A163. Then, associations were detected by probing 
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Figure 2.9 RhammA163 influences pERK sustained translocation to different 
compartments of the cell in Rhamm -/- MEFs and 10T1/2 fibroblasts. Activation of 
ERK and its trafficking was determined after transfection of RhammAI63 in either Rhamm 
-/- MEFs or 10T1/2 cells. A) Confocal images of Rhamm -/- MEFs and Rhamm -/- MEFs 
transfected with RhammAI63. The cells were imaged before and after stimulation with 
10%FBS at different timepoints as indicated in the figure. pERK was present in the 
nuclei, cytoplasm and membrane of the MEFs. However, greater fluorescence was 
evidenced in the cells that expressed RhammAIA3. This activation was also more stable 
over time in these cells. B) The presence of pERKl,2 was obvious in the nuclei of 10T1,2 
transfected with RhammA1A3 after serum stimulation and nuclear extraction at different 
timepoints when compared with its counterpart, parental 10T1/2. The images are 
representative of experiments performed in triplicate. Scale bars, 20 pm
78
2.5 Discussion
Tumour progression and metastasis are complex and intricate processes that involve a 
series of events that begin with mutations that confer the ability of a cell to ignore growth 
and migration inhibitory signals. This allows them to proliferate while ignoring contact 
inhibitory signals and accumulate additional mutations that may eventually confer a 
migratory phenotype that results in cell invasion and migration to a distant site. A 
growing number of proteins have been implicated in these processes. Our study focussed 
on one protein, RhammA163, whose expression promotes loss of contact inhibition and 
results in tumourigenic transformation in mesenchymal cells, as well as spontaneous 
metastasis in two mouse models of mesenchymal tumors [39].
With this study we were able to identify several properties that contribute to the 
oncogenicity of RhammA163. First, we demonstrated that RhammFL is not transforming but 
that it can be activated by the truncation of the N-terminal 163 amino acids. RhammAI63 
promotes loss of contact inhibition of growth and resistance to anchorage-dependent 
programmed cell death as determined by foci and colony formation in soft agar (Figure 
2 .1).
The loss of growth restraint is a key step in tumourigenesis and may be the mechanism by 
which Rhamm influences Ras mediated transformation [39]. Our results indicate that Ras 
transformation pathways are affected by the oncogenic activities of Rhamm. This is 
consistent with previous studies where high levels of RhammA163 were found in H-Ras 
transformed fibroblasts [39]. To expand on this, we demonstrated that it is RhammA163 
that is implicated in cell transformation, and that its subcellular distribution is critical for 
this functioa By using mutant inactive H-Ras we were able to reduce the transforming
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ability of RhammA163, indicating that this isoform acts upstream of Ras in 10T1/2 cells 
(Figure 2.2 B). Similarly, after using a mutant/inactive RhammA163 HABD_ construct, 
inhibition of foci formation was observed, indicating that Rhamm is required downstream 
of Ras to meet its Ras-associated oncogenic functions (Figure 2.2 A). These results 
strongly suggest that cytoplasmic RhammA163 influences the transforming capability by 
acting at multiple levels to promote cell growth advantage. This confirms our hypothesis 
that these two Rhamm isoforms have distinct functions that are dependent upon their 
subcellular distribution.
While this study confirms a role for Rhamm upstream of Ras, evidence is also presented 
implicating Rhamm downstream of Ras through association with MEK/ERK. ERK1,2 
MAP kinases are involved in cell migration and proliferation in response to growth 
factors and ECM receptor activation [53]. There is an immense number of ERK/MAPK 
substrates, necessitating the presence of regulatory mechanisms that confer ERK1,2 with 
substrate and functional specificity [54]. Spatial resolution appears to be one of these 
regulatory mechanisms. For instance, nuclear accumulation of ERK takes place after 
mitogenic stimulation; moreover, pERK presence in the nucleus is required for ERK 
induced transformation [6-8]. It is clear that Rhamm plays a role in the regulation and 
stabilization o f ERK1,2 activation [34, 48, 52, 55], however we are the first to show not 
only that RhammAI63/ERKl,2 interaction is required for Rhamm-dependent growth 
transformation (Figure 2.2 B,C), but also that RhammA163 is responsible for the stable 
translocation of pERK into the nucleus (Figure 2.9). The importance of Rhamm-mediated 
trafficking of pERK to the nucleus in cellular transformation and cell migration in 10T1/2 
cells is a subject of current study.
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In accordance with previous studies, we demonstrated that the full length isoform of 
Rhamm preferentially binds to cytoskeletal proteins (Figure 2.7 A), which is at least 
partially responsible for its localization in the cytoplasm (Figure 3.7 B). RhammFL 
possesses two tubulin binding sites, located at the N-Terminus of the sequence between 
amino acids 129-149 (RhammA163 lacks this binding site) and the other at amino acids 
727-741 at the C-terminus (Figure 2.1 D). Site directed mutagenesis using GFP-RHAMM 
fusions [22, 26] and co-localization analysis of ZsGreen-Rhamm constructs indicate that 
the N-Terminal tubulin binding site is required for its fibrillar distribution. This enhanced 
association for tubulin and cytoskeletal proteins might serve as a reservoir for Rhamm 
whereby cleavage of its N-Terminus would make it available by releasing then the active 
A163 form. Further studies are required to confirm this working model.
We were also able to demonstrate that our ZsGreen-Rhamm fusions displayed equivalent 
localization to that previously reported for wild type Rhamm. Briefly, we observed both 
isoforms of Rhamm in the cytoplasm of the cell, as well as in the nucleus decorating the 
mitotic spindle during cell division and at the cell surface inpodosomes [22, 26-28]. This 
confirmed that the fusion of ZsGreen at the N-terminus and FLAG at the C-terminus of 
Rhamm does not affect its trafficking and subcellular localization (Figure 2.5 A).
The activation o f the oncogenic properties of Rhamm by truncation is analogous to that of 
other proteins. This is the case of proteins like c-raf (-1) and Vav that get activated by 
removal of a portion of the full length protein [56, 57]. Gene rearrangement and 
recombination o f the original sequence gives rise to the active form of c-raf (-1), 
suggesting that the truncation o f the regulatory portion leads to c-raf (-1) activatioa 
Furthermore, the Vav family of Rho GEFs is composed of three isoforms. Similar to
81
Rhamm, Vav 1 is transforming when over-expressed in fibroblasts and an N-terminal 
extension of the protein inhibits Vav interactions with its downstream GTPase substrates. 
The mechanism by which RhammA163, but not RhammFL is transforming is yet to be fully 
elucidated.
Fluorescence recovery after photobleaching (FRAP) analysis is an established method to 
assess intracellular protein motility dynamics [58-60]. Here we investigated whether 
different isoforms of ZsGreen tagged Rhamm differed significantly in their fluorescence 
recovery time after photobleaching. Indeed, it was evident that ZsGreen-RhammA163 was 
more dynamic in the cytoplasm of Rhamm -/- MEFs as they presented higher 
fluorescence recovery when compared with RhammFL. In general, the fluorescence 
recovery index represents the repopulation of the bleached areas with the fluorescent 
protein present in the remaining, unbleached area of the cell. The surface diffusion 
velocity reflects the state of the labelled protein, with the key assumption being that 
unbound protein diffuses faster than bound protein. Therefore, these results can be 
explained by the stable association of RhammFL with rigid components of the cell, such as 
cytoskeletal tubulin, actin or even Dynein/dynactin-microtubules. Such associations have 
been shown previously with Rhamm [20, 22, 26]. It is possible that the second tubulin 
binding site in the Rhamm N-terminus makes it more likely to bind to either those 
cytoskeletal proteins or to other scaffolds, such as Filamin a (FLNA), Spectrin a 
erythrocytic 1 (SPTA1), Spectrin (3 non-erythrocytic 4 (SPNB4), or Actininl (ACTN1) 
that attach it to the cytoskeleton. Based on its increased mobility, it is likely that a 
substantial portion of RhammA163 is free in the cytoplasm. This population of RhammA163 
may arise as a result of cleavage of RhammFL. This may help to explain its enhanced
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oncogenic activity, which could be due to an increased ability to traffic to subcellular 
compartments that RhammFL does not have access to. Interestingly, when we transfected 
10T1/2 cells with our ZsGreen-Rhamm constructs, the distribution of RhammFL was far 
less fibrillar than in Rhamm -/- MEFs (Supplemental figure 2.1 A). 10T1/2 cells have 
higher expression of RhammFL [20] and it might be that endogenous Rhamm in these cells 
are binding with higher affinity to cytoskeletal proteins in the cells inhibiting interactions 
of ZsGreen-RhammFL. In support of this hypothesis, FRAP experiments performed in this 
cell line demonstrated that RhammFL was almost as dynamic as RhammA163 
(Supplemental figure 2.IB). Despite the fact that the two cell lines used for these 
experiments are mouse fibroblasts, they come from different genetic backgrounds. Our 
results lead us to think that ZsGreen-RhammFL is less likely to bind to tubulin 
(Supplemental figure 2.1C) and more available to bind to ERK in the cytoplasm of 
10Tl/2s (Supplemental figure 2.ID). This theory, although in its very early stages, agrees 
with our previous one that suggests that RhammA163 is free in the cytoplasm to bind to 
ERK and to target it to the nucleus of the cell, however differs as to the role of RhammFL, 
whereby “free” ZsGreen-RhammFLco-localizes more with pERK in 10T1/2 cells than the 
tubulin bound ZsGreen-RhammFL in Rhamm -/- MEFs. We also speculated that 
dimerization o f endogenous Rhamm ZsGreen-RhammFL was not responsible for this 
change in distribution because transfection of ZsGreen-RhammFL in Rhamm -/- that were 
stably expressing either RhammFL or RhammA163 did not influence the fibre-like 
appearance of RhammFL in this cell line to the extent of transfection into 10T1/2 cells 
(Supplemental figure 2.IB).
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It is important to note that our MALDI-TOF MS analysis of RhammFL/A163 binding 
partners has several limitations. Cytoskeletal proteins are much more abundant than other 
intracellular proteins, and this bias in our assay may have obscured other potential 
RHAMM protein partners not only in the cytoplasm, but also in the nucleus and 
membrane o f the cell. While further studies are required for us to come to a better 
understanding o f the molecular interactions that make RhammA163 an oncoprotein, the 
present study provides some meaningful insight in the transformation process. In 
summary, we demonstrated that the expression of RhammA163 in mouse fibroblasts 
induced loss of contact inhibition of growth and resistance to anchorage-dependent 
programmed cell death. These phenomena can be explained by the presence of a feedback 
mechanism in which RhammA163 acts at the level of Ras and MEK/ERK, promoting 
activation of these substrates and inducing a cascade of events that result in cell 
transformatioa In addition to RhammA163 interactions with ERK1,2, in the cytoplasm, this 
transforming isoform also promotes translocation of pERKl,2 to the nucleus and 
stabilizes it there for extended periods of time.
2.6 Conclusion
A naturally occurring Rhamm isoform with a 163 amino acid N-terminal truncation, in 
contrast to the full length protein, has oncogenic activity in mouse fibroblasts. This 
activity may be due in part to observed differences in cellular localization, a differential 
interaction with Ras and MEK/ERK in the cytoplasm, and by an increased ability to 
recruit pERK 1,2 to the nucleus.
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Metastasis is the deadliest aspect of prostate cancer (PCa), and influences its prognosis 
and treatment. Current diagnostic methods fail to identify patients with occult metastases, 
highlighting the need for more effective prognostic indicators of disease progressioa 
Through immunostaining of prostate tissues we evaluated the prognostic value of the 
metastasis blocking, anti-CD151 antibody 1A5 (mAb 1A5), in detecting PCa disease 
progression and metastasis. CD151 immunoreactivity was assessed by 
immunohistochemistry using mAb 1A5 in PCa tissue from 99 non-metastatic patients 
that underwent radical retropubic prostatectomy (RRP) and 38 biopsy samples from 
patients that did not undergo RRP but exhibited metastasis during their follow-up. To 
gain additional insight into the predictive value of mAb 1A5 compared to global CD151 
expression, CD151 mRNA levels in PCa were evaluated using publically available 
microarrays. Immunoreactivity as assessed by mAb 1A5 was higher in malignant tissue 
than in benign tissue adjacent (p=0.01) or distant from the tumor (p<0.01). CD151 
staining in the prostate luminal epithelium correlated positively with time to biochemical 
recurrence (p=0.023) in the RRP cohort. CD151 immunoreactivity in diagnostic biopsy 
samples was prognostic for the occurrence of overall metastasis (p<0.01), bone metastasis 
(p=0.01), and hormone resistance (p<0.01). Microarray analysis of PCa revealed no 
significant change in CD151 expression across clinical stage nor did it correlate with 
metastasis, disease relapse, or survival. Multivariate analysis indicates that CD151 
immunoreactivity with mAb 1A5 is an independent prognostic marker that indicates 
significant risk of early metastasis. These results indicate that mAb 1A5 staining of 
CD151 correlates with biochemical recurrence and metastasis of PCa. The absence of a
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similar correlation with CD151 mRNA suggests that epitope-specific CD151 
immunoreactivity may serve as a biomarker to help identify PCa patients with a high risk 
for rapid progression.
3.2 Introduction
Prostate cancer (PCa) is the most common malignancy in North American men, 
accounting for 10% of all cancer-related deaths in 2010 [1]. With the ubiquitous use of 
prostate specific antigen (PSA) testing (normal <4ng/mL) and PCa screening programs, 
an increasing number o f low grade early PCa are being diagnosed. Due to the low overall 
risk of these cancers developing into clinically-relevant disease, many patients opt for 
active surveillance rather than radiation or radical retropubic prostatectomy (RRP). In a 
significant number of these cases, disease progression can accelerate and pose an elevated 
risk that may have been avoided with earlier intervention [2]. The vast majority o f cancer- 
related mortalities are due to metastatic disease [3].
Current diagnostic tools such as PSA, digital rectal examination (DRE), biopsy, Gleason 
score, TNM stage (Tumour, lymph Node invasion, and distant Metastais), Partin’s 
nomogram and tables [4], and D’Amico’s risk stratification scheme [5] accurately predict 
PCa-specific mortality [6]. However, these tools do not accurately identify those cases 
that harbour occult metastatic disease [7-9]. PSA in particular is a valuable tool for 
disease diagnosis and the evaluation of treatment response, but it lacks the sensitivity and 
specificity necessary to predict metastasis [10-12]. The inability of PSA to determine 
disease progression is highlighted by the discrepancy between the lifetime risk of PCa
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diagnosis (16%) and death from PCa (3-4%).[13-15] Although there is a well-established 
association between biochemical recurrence and PCa-specific death,[16, 17] it remains 
difficult to identify patients likely to experience biochemical recurrence by pathology or 
other currently available diagnostic techniques. [17]
CD151 (GP27, SFA-1, PETA-3) is one of 33 members in the mammalian Tetraspanin 
family and is characterized by four transmembrane domains. It is ubiquitously expressed, 
but is predominantly found in the plasma membrane of epithelial cells, endothelial cells, 
smooth muscle cells, and platelets. [18-21] Several related functions have been attributed 
to CD151, including platelet aggregation,[22] cell adhesion,[23] cell migration,[24, 25] 
tumour cell invasion and metastasis.[21, 26, 27] Its loss in humans and experimental 
mouse models leads to basement membrane failure, including skin blistering and renal 
failure.[28, 29] CD151 is frequently up-regulated in cancer.[21] Its expression is 
associated with poor outcome in several cancers, including esophageal cancer,[30] 
hepatic cancer,[31, 32] lung cancer,[33] and clear cell renal carcinoma[34]. While 
previous studies have shown that CD151 expression in PCa is a better prognostic 
indicator than Gleason grading,[35] a role for CD151 expression in the prediction of 
metastasis has not been explored.
We have shown previously that CD151-specific monoclonal antibody 1A5 (mAb 1A5) 
prevents metastasis by inhibiting tumour cell intravasation without affecting primary 
tumour growth, tumour cell arrest, extravasation, or growth at the secondary site. [27] In 
vivo, the unique ability of mAb 1A5 to strongly inhibit migration is due to enhanced 
tumour cell-matrix interactions. Because other CD151-specific antibodies have been 
described to promote tumour cell migration,[36, 37] we surmised that mAb 1A5 might
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recognize an epitope of CD151 that is particularly relevant for PCa cell migration and 
metastasis. To test this, CD151 immunoreactivity was assessed by immunohistochemistry 
using mAh 1A5 in two cohorts, 99 cases from patients that underwent radical retropubic 
prostatectomy (RRP) and 38 biopsies from patients who exhibited metastasis during their 
follow-up but who did not undergo RRP.
Here, we show that CD151 immunoreactivity as determined using mAb 1A5 is a 




A total of 137 patients with PCa were included in this retrospective study with a mean 
follow up of 12.1 years. The first cohort of 99 cases had undergone RRP between 1994- 
1998 at the London Health Sciences Centre with pathological stage pT2 - pT3 PCa 
(Tables 3.1 and 3.2). A second cohort of 38 cases was comprised of diagnostic biopsy 
specimens from patients at the same center who did not undergo RRP and developed 
metastatic disease detected during their follow up (Table 3.3). Pathological staging was 
re-evaluated according to the TNM staging regarding presence and size of prostate 
tumour, Lymph noede metastasis and distant metastasis (AJCC 2002). Patient 
characteristics and disease-related outcomes were obtained from a review of the medical 
records (Tables 3.1-3.3). This study obtained approval from an independent local Ethics
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Committee (UWO REB #15084E) (Appendices B-D) and obtained the informed consent 
from all patients for the research use of their tissues (Appendix A).
Immuno histoche mistry
The mouse monoclonal antibody 1A5 specific for CD151 was generated using a 
subtractive immunization approach as previously described [38, 39]. Formalin-fixed, 
paraffin-embedded tissue blocks were cut into 4 pm sections and mounted onto positively 
charged glass slides. The tissue was deparaffinized and rehydrated using the xylene, 
graded ethanol, and water method. A two-step epitope retrieval was performed whereby 
tissue sections were boiled in the microwave in 10 mM Sodium Citrate, 0.05% Tween 20 
pH 6.0. The slides were then allowed to cool down, washed with PBS 0.2% Triton-X, and 
incubated with pre-warmed pepsin (digest-all™ 3, Invitrogen) for 3 minutes. After 
washing with PBS-Triton-X, the specimens were stained using the Ultra Vision Detection 
System (Thermo-Scientific). CD151 mAb 1A5 was diluted 1:800 in 1% BSA in PBS, and 
CD151 mAb llG 5a (abeam) was diluted 1:100 in 1% BSA in PBS. Samples were then 
counter stained with Hematoxylin and mounted with Cytoseal (Thermo-Scientific). 
Negative controls were prepared using the identical treatment with omission of the 
primary antibody. Non-immune mouse IgG was used as an additional negative control.
CD151 expression analysis
CD151 expression in the RRP and biopsy cohorts was categorized as negative (score=0), 
weakly positive (score=l), moderately positive (score=2) or strongly positive (score=3) 
independently by two pathologists who had no knowledge of the patient’s clinical status. 
A consensus was reached where any discrepancy was identified. To determine the
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statistical significance of mAb 1A5 immunoreactivity, specimens were divided into 
negative (score=0) and positive (score=l-3). CD151 protein expression analysis was 
performed in cancerous areas and benign tissue adjacent and distant from areas of tumour. 
Biochemical recurrence after RRP was defined as two consecutive PSA measurements 
greater than 0.2ng/mL. Hormone resistance was defined as the progression of metastatic 
lesions and/or an increase in testosterone levels over original castration levels and/or 
significant PSA increase in at least two consecutive measurements while the patient was 
receiving hormone therapy. Bone metastasis was defined as presence of metastatic lesions 
on a bone scan.
Statistical analysis
All statistical analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, 
NC). The primary endpoint for the cohort of patients who had REP was biochemical free 
survival; the primary endpoint for the biopsy cohort was metastasis free survival. 
Correlations between 1A5 immunoreactivity and biochemical free survival in malignant 
areas compared to benign areas were analyzed by McNemar’s chi-square test. Kaplan- 
Meier plots were used to assess the univariate and multivariate analysis of biochemical 
free survival and metastasis and groups comparison was made using the log-rank test. The 
Cox proportional hazard model was applied for multivariate analysis. In all statistical 
analyses, a two-sided P < 0.05 was considered statistically significant.
Gene expression profiling studies analyzed for the PCa data were obtained from the 
NCBI GEO. These included GDS2545 (n=171)[40], GDS1439 (n=19)[41], GSE3933 
(n=l 12,)[42], and GSE6099 (n=102)[43]. Datasets were categorized according to their 
clinical diagnosis and analyzed by ANOVA with post-test analysis for linear trend.
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CD151 expression levels were extracted from publically available expression dataset 
GDS3113 (n=3/tissue) [44] to demonstrate relative levels of CD151 expression in prostate 
compared to other tissues.
Role of the funding source
The study sponsor (London Health Sciences Centre) and sources of funding (Canadian 
Cancer Society Research Institute and the US National Institutes of Health) had no role in 
the design of the study, collection, analysis, or interpretation of the data, or in writing the 
report, or the decision to publish the results. Interpretation of the data and the final 
content of this report were approved by all authors. The corresponding author had full 
access to the data and takes full responsibility in submitting the report for publication.
3.4 Results 
Patients
For the RRP cohort, the patient characteristics, pathological and clinical outcomes are 
summarized in tables 3.1 and 3.2. The mean age of these patients at the time of diagnosis 
with PCa was 62.4 years ±5.7 SD, initial PSA median was 9.7ng/mL ±5.2 SD and median 
follow-up was 12.1 years ±1.6 SD. The clinical tumour stages (TNM staging) were as 
follows: 36.4% were classified as T l, 55.5% as T2, 2% as T3 and 6.1% as unknowa The 
pathological T stages were distributed as: 60.6% in pT2, 35.4% in pT3, and 4% in pT4. 
Gleason 8 or higher was recorded in 27.3% of the patients while 72.7% of patients had a 
score of 7 or less. Positive margins were noted in 23.2% of cases and 12% had positive
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seminal vesicles at the time of the RRP, 35.4% developed biochemical failure, 4.2%
metastatic disease and 1% hormone resistance.
PSA (ng/mL)
Follow up (years)
9.7 ± 5.2 SD
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Table 3.1 Demographic and clinical staging information of patients that underwent 

































Table 3.2 Pathological and clinical outcomes of patients that underwent RRP at the 
London Regional Cancer Program between 1994 and 1998 («=99)
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Table 3.3 summarizes the demographic information from the biopsy cohort of patients. 
Median age was 66.7± 9.76 SD years. From this group of patients, 15.7% were at clinical 
stage Tl, 50% at T2, 26.3% at T3, and 2.6% at T4 at the time of diagnosis. Gleason 7 or 
lower was reported in 50% of the patients. Bone metastasis was present in 89.4% of 
patients with metastatic disease. 81.5% developed hormone resistance during their 
treatment.
Variable










Hormone resistance 31 (81.5%)
Bone metastasis 34 (89.4%)
Table 3.3 Demographic and clinical staging information of patients that developed 
metastasis during follow up at the London Regional Cancer Program between 1994 
and 1998 («=38)
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CD151 is expressed in basal epithelium of prostate tissue.
The mAb 1A5 was generated previously using a subtractive immunization approach that 
was designed to generate a library of function-blocking antibodies for metastasis. [38] We 
first wanted to determine if mAb 1A5 could detect CD151 in paraffin embedded prostate 
tissue. To determine if  mAb 1A5 staining is predictive of disease progression we 
compared immunostaining of mAb 1A5 with the commercially available mAb 1 lG5a. As 
expected, some immunoreactivity for both antibodies was observed in normal prostate 
epithelium and prostate adenocarcinoma (figure 3.1). However, mAb 1A5 staining was 
significantly higher in the tumor area (figure 3.1A) when compared with benign tissue 
adjacent to the tumor (p=0.01) (figure 3.IB) and benign tissue distant from the tumor 
(p<0.01) (figure 3.1C). In contrast to the immunoreactivity observed with mAb 1A5, 
mAb 1 lG5a detected CD151 expression in the membrane and cytoplasm of both benign 
prostate epithelium and tumor (figure 3.2, right). Moreover, mAb llG5a signal was 
evident in fibroblasts (red arrow) and immune cells which are known to express CD151 
but which are not stained by mAb 1A5 (not shown). These divergent staining patterns 
suggest that mAb 1A5 detects a distinct pool of CD151 that is present at elevated levels in 
the tumor.
CD151 staining on RRP samples is prognostic of biochemical recurrence
We then wanted to confirm if by staining patient samples with mAb 1A5 we could detect 
more aggressive subpopulations of cells and could predict patient prognosis. In order to
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Figure 3.1 CD151 is expressed in basal epithelium of prostate tissue. CD151 
Immunoreactivity was detected by immunohistochemistry (IHC) using mAb 1A5 on 
formalin fixed, paraffin embedded primary tumors (RRP) stained following the 
HRRP/DAB method. CD151 staining was higher in tumor area (A) (20x) than in benign 
tissue close to the tumor (B) (p=0.01) and benign tissue distant from the tumor (C) 
(p<0.01) Scale bars left, 50 pm, right, 8 pm.
104
mAb1A5 mAb 1 lG5a
Figure 3.2. mAb 1A5 recognizes a different subpopulation of CD151. CD151 
Immunoreactivity was detected by immunohistochemistry (IHC) using mAb 1A5 (A, left) 
Bar 50pm) and mAb llG5a (A, right), on formalin fixed, paraffin embedded primary 
tumors (RRP) stained following the HRRP/DAB method. CD151 as detected by mAb 
1A5 was expressed mostly in basal epithelium of prostate tumor tissue whereas mAb 
llG5a detected different subpopulations of CD151. CD151 is present throughout the 
membrane and cytoplasm of prostate epithelium (black square), fibroblasts (red arrow). 
Figures 2B left are representative images of samples from patients that did not develop 
biochemical recurrence that were stained with mAb 1A5. Patient tissues on figures on the 
right were stained with mAb 1 lG5a.
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do that we generated Kaplan-Meier curves by correlating Biochemical free survival data 
with CD151 immunoreactivity in epithelium of prostate tissue after RRP. Log-rank
analysis of the biochemical free survival data of patients with PCa demonstrated a strong 
correlation between biochemical recurrence and positive mAb 1A5 staining of CD151 
(p=0.023) (figure 3.3).
On the other hand, CD151 staining using mAb 1A5 in benign tissue adjacent to the tumor 
and benign tissue distant from the tumor failed to demonstrate association with 
biochemical recurrence. Moreover, 85% of the patients that had PSA recurrence were 
CD151 positive in the tumor area. In contrast, staining with 1 lG5a was not predictive of 
survival nor did it correlate with biochemical recurrence. This is represented in figure 
3.2B for two patients who did not developed biochemical failure. Tumor tissue was 
stained with mAb 1A5 (left) with no significant detection of signal. However, serial tissue 
sections from the same patients stained with mAb llG 5a (right) showed strong CD151 
immunoreactivity. Based on these data we can conclude that staining with mAb 1A5 may 
be useful in detecting those patients at risk of biochemical recurrence.
CD151 immunoreactivity associates with earlier onset of metastasis and adds 
predictive value for hormone resistance
After we found significant predictive value of mAb 1A5 in RRP specimens, we attempted 
to determine if this staining would be predictive of progression to metastasis. Biopsies 
were obtained from patients whom, at the time of PCa diagnosis did not undergo RRP,
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and eventually developed metastasis identified at follow-up. In those biopsies, CD151 
immunoreactivity positively correlated with overall metastasis (p<0.01), bone metastasis 
(p=0.01), and hormone resistance (p<0.01) (Figure 3.4). In fact, 76.3% of the patients 
with elevated CD151 staining on the diagnostic biopsies developed hormone resistance; 
41.3% within the first three years of treatment.
Years since RRP
Log-rank p=0.023
Figure 3.3 CD151 staining on RRP samples is prognostic of biochemical recurrence
Kaplan-Meier curves were generated using the Biochemical free survival data against 
CD151 immunoreactivity in epithelium of prostate tissue after RRP. Log-rank analysis of 
the biochemical free survival data of patients with PCa showed correlation between PSA 












Figure 3.4 CD151 immunoreactivity associates with earlier onset of metastasis.
Kaplan-Meier survival curve performed with data from patients that developed metastasis 
during their follow-up at the London Regional Cancer Program between 1994 and 1998. 
Log-rank analysis of the survival curve shows association between CD151 
immunoreactivity on diagnostic biopsy samples and earlier onset of metastasis (p=0.001).
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Stepwise Cox proportional hazards regression was used to obtain a multivariate model. 
PSA (pO.OOl) and CD151 immunoreactivity (p=0.009) entered the model. CD151 
positive staining was still significant after adjusting for PSA levels showing that patients 
with high PSA (p<0.01) and CD151 staining (p<0.01) have the highest risk of developing 
metastatic disease. CD151 immunoreactivity demonstrated additional risk of earlier 
metastasis as an independent variable improving the model. For display purposes PSA 
was categorized as 20ng/mL or higher and lower than 20ng/mL, and was associated 
CD151 positive or negative immunoreactivity as detected by mAb 1A5 and the time to 
metastasis using the Kaplan-Meier technique (figure 3.5).
PCa expression microarray data was evaluated to confirm that the detection of CD151 by 
mAb 1A5 was due to the increased epitope availability and not due to increased gene 
expression. In comparison to other normal tissues, expression of CD151 in prostate tissue 
is greater than in testis, liver, and brain, but lower than in lung, breast, and heart 
(Supplemental figure 3.1). Three distinct datasets assessing CD151 expression in normal 
prostate and PCa were evaluated. Within these samples CD151 expression remained 
unchanged (figure 3.6 A-C). Expression analysis in epithelial cells by laser capture 
microdissection confirmed that the epithelial cells, in its progression to cancer cells did 
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Figure 3.5 Patients with CD151 positive staining and high PSA have increased risk 
of developing metastasis. Kaplan Meier curves of CD151 expression and PSA in 
patients that developed metastatic disease during follow up at the London Regional 
Cancer Program between 1994 and 1998. Stepwise Cox proportional hazards regression 
was used to obtain a multivariable model. PSA (p<0.001) and CD151 immunoreactivity 
(p=0.009) entered the model.
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Figure 3.6 Expression analysis of CD151 mRNA in PCa progression. Public 
microarray datasets were obtained through Gene Expression Omnibus (GEO) at The 
National Center for Biotechnology Information (NCBI). Normalized expression data 
obtained for CD151 was plotted for normal prostate, PCa, and metastatic prostate in panel 
A-C (GDS2545 (n=171) [40], GDS1439 (n=19) [41], and GSE3933 (n=112) [42], An 
analysis of individual cell populations obtained by laser capture microdissection (panel D, 
GSE6099, n=102) [43] was used to confirm that the epithelial derived cancer did not alter 
expression of CD151 during progression.
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3.5 Discussion
In this study we demonstrate that detection of a specific pool of CD151 in PCa tissue 
from RRP specimens is associated with earlier biochemical failure of patients. These 
early failures might represent localized disease at the time of RRP or a subset of patients 
that harbored unrecognized micrometastatic disease. CD151 expression, as detected by 
monoclonal antibody 1A5, may predict patients with elevated risk for failure and 
potentially could avoid the associated morbidity of RRP in patients without significant 
chance of cure. These early failures have been shown to respond poorly to local salvage 
with external beam radiation therapy presumably because early PSA failure is the result 
of occult micrometastatic disease. [45] This emphasizes the need for a more accurate 
diagnostic tool to avoid overtreatment and to detect those who have an increased risk of 
metastatic disease and death.[46] Especially because over treating patients is problematic. 
A recent European screening randomized trial confirmed that 48 patients need to be 
treated in order to save one life. [7, 47] The associated morbidity of treating men with low 
risk PCa creates significant undue stress on patients and is also a significant burden 
economically. Strategies like active surveillance have helped to reduce this morbidity, but 
accurate markers which can define high risk patients in the early stages of disease are 
lacking. [48] Effectively tailoring patient treatment requires more accurate markers to 
identify those patients with an increased risk of developing biochemical failure, 
metastatic disease, hormone resistance, and death.
The findings from our study demonstrate that mAb 1A5 detects a pool of CD151 that is 
elevated in tumors, highlighting the ability of CD151 staining to predict early disease
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recurrence. Therefore, CD151 detection in prostate adenocarcinoma tissue identifies 
patients at higher risk of biochemical failure, which may benefit from further treatments 
such as chemotherapy for presumed micrometastatic disease or pelvic and nodal 
radiation. This data can be made available both at the time of TRUS biopsy and 
immediately after surgery with the pathology report, allowing earlier intervention and 
avoiding unnecessary delays in higher risk patients.
In patients with metastatic disease detected during their follow-up, CD151 staining was 
independently associated with shorter metastasis free survival, and progression to bone 
metastasis and hormone independence, adding accuracy to the multivariate model. Whilst 
we demonstrated a clear biological rationale for the association of CD151 positivity with 
the development o f metastasis, the link with castrate resistant disease is likely complex. 
We theorize that the ability of PCa to metastasize results in an increase in tumor mass 
allowing for subsequent alterations within the malignant cells androgen receptor 
culminating in a clonal population of androgen independent cells. Regardless of the 
mechanism, these data consistently suggest that CD151 immunoreactivity early in the 
disease is associated with worse prognosis. To further validate the functional predictive 
value of the 1A5 antibody, a significantly larger database should be assessed.
This, to the best o f our knowledge, is the first study to use the 1A5 mAb to measure 
immunoreactivity of CD151 in human prostate tissue but it is consistent with the findings 
of others. Ang et al. showed association between CD151 staining and PCa 
progression.[35] They found a positive correlation between CD151 expression and cancer 
dedifferentiation, a hallmark indicator of disease progression, and patient death. Gleason
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score association with recurrence was not strong enough to reach statistical significance 
in our cohort. This could result from antibody differences used to detect the levels of 
CD151. Previous CD151 studies used different antibodies that recognize intracellular 
epitopes of CD151. 1A5 mAb was produced by subtractive immunization [38] against an 
extracellular epitope of CD151 that was necessary for cancer cell metastasis in animal 
models.[27] It was shown that mAb 1A5 blocked CD151 induced cell migration and 
reduced spontaneous metastasis by more than 80%, demonstrating the importance of 
CD151 in metastasis. mAb 1A5 might specifically recognize a pool of CD151 that is 
relevant for clinical metastasis.
CD151 expression has been associated with metastasis and progression in other types of 
cancer. In aggressive mammary ductal carcinoma in situ, CD151 expression correlates 
with markers of progressive disease, including elevated Erk and c-Akt activation and 
increased cell proliferation [49]. Changes in CD151 expression are associated with poor 
prognosis of colon cancer patients [50]. In one of the most invasive forms of human 
cancer, pancreatic adenocarcinoma, there is an increased association of CD151 with 
integrin a6(34 that is thought to contribute to its aggressive nature [51]. The association 
of CD151 with integrins may play an important role in the dissemination of cancer cells. 
A major mechanism by which CD151 supports cancer progression is through integrin 
regulation, and CD151 has been found to regulate integrins containing either a3 [52] or 
a6 [53] subunits. Blocking CD151 function inhibits the metastasis of human epidermoid 
carcinoma and fibroscarcoma without influencing growth of the primary tumor cells [27]. 
Since CD151 is generally associated with the migratory phenotypes of many cancers, the
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association of CD151 with aggressive forms of prostate cancer reported here is likely to 
have functional significance to disease progression.
This study is limited by the retrospective collection of the demographic and clinical data. 
Overall survival analysis was limited, despite a follow-up of 12.1 years ±1.6 SD, because 
there were only 2 deaths in the group of patients who underwent RRP. Another limitation 
is the number of patients in the group of biopsy specimens which can limit the 
interpretation of the results, however because of the significant findings we have decided 
to include them in this manuscript.
Further investigation is required into the role of CD151 in predicting metastatic variants 
of PCa. We have demonstrated the ability to reliably perform immunohistochemical 
analysis on prostate biopsy specimens that have been embedded in paraffin for significant 
periods of time. This suggests that not only can CD151 be used as tool to add to the initial 
treatment decision but could also be useful in assessing patients suitability to undergo 
potentially morbid salvage treatments.
In conclusion, the CD151 staining with mAb 1A5 is associated with earlier biochemical 
failure, metastasis and hormone resistance. In conjunction with PSA measurement, 
detection of CD151 adds significant prognostic value to predict biochemical failure and 
the outcome of patients with PCa and might help to stratify and treat patients accordingly.
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Chapter 4
General discussion and conclusions
4.1 Thesis summary and Significance
Tumour cell migration has an enormous influence on cancer progression since it accounts 
for tumour dissemination to cause not only local recurrence, but also distant metastasis 
[1-4]. It is, therefore, not surprising that many researchers are focusing their efforts on 
dissecting in detail the mechanisms by which a cell gains the ability to productively move 
from a primary tumour to a distant site, the implications that this has for tumour 
metastasis, and, lastly, the therapeutic pathways that can be followed to prevent this 
phenomenon from occurring. In order to find any therapeutic agent to inhibit the cell’s 
ability to detach from the primary tumour and migrate towards a distant site, molecular 
microdissection of the mechanisms involved in this process is required.
Multiple attempts to develop potential therapeutic agents to reduce tumour cell migration 
have been made. In fact there are currently a number of clinical trials evaluating reagents 
that target cell motility [5-8]. However, due to the complex mechanisms involved and the 
high degree o f specificity that they must exhibit in order to avoid off target effects this 
endeavour is very challenging. While some groups focus on developing new anti- 
migratory drugs as therapeutic reagents, other laboratories have concentrated on finding 
other applications, for instance, using signatures of motogenic proteins to predict the 
outcome of cancer patients [9-11]. Over the long term, the development of a deeper
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knowledge of the molecular mechanisms of cancer cell migration will potentially 
translate into the clinics in the future.
Of particular interest for us are two proteins that have been demonstrated to have an 
effect on cell migratioa The first is CD151 for which a mouse monoclonal antibody was 
proven to significantly inhibit cell migration away from the primary tumour and invasion 
of surrounding stroma. This inhibition resulted in significant reduction of spontaneous 
metastasis after injecting HEp3 cells in both a chicken embryo model and in SCID mice, 
along with experimental metastasis in a chicken embryo model [12]. Unfortunately, since 
CD151 is a ubiquitous protein and CD151 is expressed in platelets and endothelial cells, 
this antibody induced platelet aggregation in human blood making it unsuitable for cancer 
therapy (data not shown). Nevertheless, it is a prognostic biomarker for biochemical 
recurrence and metastasis in prostate cancer.
The second protein, Rhamm, is currently being used as a therapeutic target for AML and 
MM and has completed phase II clinical trials with minimal patient toxicity and 
favourable clinical results [13-15]. Under normal physiological conditions, RHAMM is 
not expressed in most human cells. However, during cancer progression, it is highly 
overexpressed and this expression is often linked with poor clinical outcome. This, added 
to the restricted expression of RHAMM during wound healing and tumour formation and 
progression, makes it a more specific therapeutic target for tumour treatment inducing 
less adverse side effects. However, to date, the molecular mechanisms by which one 
isoform of this protein, RhammAI63, influences transformation and oncogenicity have not 
been fully established.
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The aim of this study was to demonstrate the avenues by which seemingly different cell 
migration inducing proteins can be studied in order to help to achieve a deeper 
understanding o f the transformation process and to predict the clinical outcome of cancer 
patients and therefore treat them accordingly, diminishing not only adverse effects, but 
also the onset of metastasis. We integrated the use of an anti-metastatic/anti-migratory 
monoclonal antibody to CD151, 1A5 [16], to predict disease recurrence and metastasis 
free survival in patients with prostate cancer. Additionally, we investigated the effect that 
two different isoforms of an oncoprotein with a significant effect on cell migration, 
RhammFL/A163, have on subcellular localization and transforming events in mouse 
fibroblast cell lines.
In the third chapter of this thesis we demonstrate the ability of the mouse monoclonal 
antibody 1A5 to identify a subpopulation of CD151 present mostly in patients who 
developed biochemical recurrence after having radical retropubic prostatectomy (Figure 
3.2) and in patients that developed metastasis during their follow up (Figure 3.3). 
Database scavenging for gene expression proved that CD151 mRNA and protein 
expression are not significantly different at any stage of prostate cancer progression 
starting from normal prostate to prostate cancer and metastasis (Figure 3.6). This 
indicates that in prostate cancer, as opposed to other cancers such as hepatocellular 
carcinoma [17], non-small cell lung carcinoma [18], and clear cell renal cell carcinoma 
[19], CD151 is not overexpressed [20-23] but there is rather a potentially mutated 
subgroup of this protein that confers cells with a more aggressive phenotype. Based on 
the fact that this antibody had an effect on the more migratory cells in vivo by inhibiting 
their ability to detach from the primary tumour, invade through surrounding tissue, and
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migrate to a secondary site to cause metastasis [12], we hypothesized that mAh 1A5 was 
able to detect that subpopulation of CD151 that actually conferred the cells with 
migratory/metastatic abilities. After performing immunohistochemistry on paraffin 
embedded prostate cancer specimens, we demonstrated that the antibody detects CD151 
in a subset of patients that later on developed biochemical recurrence in the RRP cohort 
and metastasis in the biopsy cohort (Figure 3.3). These findings are of pivotal importance 
since we were able to detect which patients are at higher risk of recurrence or metastasis. 
We suggest that CD151 immunoreactivity be assessed with this antibody in diagnostic 
biopsies to help clinicians to assess which patients are at higher risk of recurrence which 
will dictate the treatment options for the patient. The epitope targeted by this antibody, its 
dynamics of recognition, and the mechanisms by which this subgroup of CD151 
associates with metastasis and biochemical recurrence are subjects of study by our group.
In a separate study described in chapter 2, we demonstrated that a naturally occurring 
isoform of Rhamm that lacks the first 163 N-Terminal amino acids is transforming, while 
RhammFL is not, indicating that Rhamm may be activated to its oncogenic potential by 
truncation o f key inhibitory amino acids. Microdissection of the initial steps of the 
transforming mechanism of RhammAI63 revealed that this isoform confers the cells with 
growth transformation potential (Figure 2.1). Here, we demonstrate that RhammA163 owes 
its transforming abilities to at least two mechanisms in 10T1/2 fibroblasts. The first 
mechanism is the ability to induce loss of contact inhibition of growth as detected by foci 
formation experiments and resistance to anchorage-dependent programmed cell death 
(anoikis) (Figure 2.1).
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It is now well known that the process of transformation from normal to tumourigenic cells 
involves a cascade of events that are triggered by a combination of oncogene 
overexpression and inhibition or loss of tumour suppression [24, 25]). This cascade starts 
with simple mutations and progresses to the point where cell cycle regulation is no longer 
existent [26]. Hanahan et al, 2001 postulated six players in the cascade of events required 
for tumour progression. These are, “Self sufficiency in growth signals, insensitivity to 
growth-inhibitory signals, evasion of programmed cell death, limitless replicative 
potential, sustained angiogenesis, and tissue invasion and metastasis” [25], In this study, 
we show that RhammAI63 makes 10T1/2 fibroblasts insensitive to contact-dependent 
growth-inhibitory signals and able to evade anchorage dependent programmed cell death. 
This is not surprising since it has been postulated that Rhamm expression induces the loss 
or inactivation of tumour suppressor genes such as BRCA1 [27, 28], and p53 [29] 
resulting in the cell’s proliferation advantage. In addition, several scientists have 
documented the role of Rhamm in cell migration and in cell cycle regulation, 
demonstrating role of this protein in multiple steps of the tumourigenic transformation.
The second mechanism by which Rhamm induces transformation is associated with its 
subcellular compartmentalization. Here, we demonstrated that RhammFL is bound to 
cytoskeletal proteins whereas RhammA163 has a much wider distribution and mobility 
within the cytoplasm (Figure 3.5). We postulated that similarly to c-raf (-1) and Vav [30, 
31], RhammFL undergoes either transcriptional or post-translational modifications that 
give rise to a shorter, transforming form, RhammA163. It may be that the full-length form 
needs to detach from these cytoskeletal proteins be able to traffic to key sites such as the 
nucleus.
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4.2 Strengths and limitations
I was fortunate to have the opportunity to work in two labs that are located at the London 
Regional Cancer Program. This makes it possible for us to come into contact with 
patients and clinical oncologists, as well as, attendance to oncology grand rounds which 
help immensely to have a broader knowledge of the clinical implications and possibilities 
of our current research.
4.2.1 CD151 immunoreactivity predicts early biochemical failure and
metastasis in prostate cancer.
This is the first study that has used the mAb 1A5 to assess immunoreactivity of CD151 in 
human prostate cancer. We strongly believe that this antibody is an asset due to its 
intrinsic properties. Contrary to many other antibodies [32], 1A5 was created by an 
unusual technique named subtractive immunization that allows for the production of 
antibodies specific to antigens present in highly metastatic cells and disregarding epitopes 
shared by metastatic and non-metastatic cells [16]. This confers the antibody with the 
ability to recognize a subpopulation of cells that are more aggressive, making it possible 
for us to predict which patients have more aggressive cancers. Moreover, studies 
performed by our group and others indicate that 1A5 recognizes specifically CD151 
regardless of binding state or associated proteins [16, 33]. Other commercially available 
antibodies recognize CD151 only when it is in a binding complex with different integrins, 
which, although informative, may obscure the results and requires further interpretation
[32].
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In addition, the patients included in this study had an average of 12.1 years of follow-up. 
This is important in the context of prostate cancer since it is a very slow growing disease 
and the length of the surveillance on these patients is pivotal in detecting late disease 
recurrence and onset of metastasis. Comparison of our study with others positions us 
among the retrospective studies with the longest follow up [17-19, 34-37].
This study is limited by its retrospective nature. Furthermore, even though we initially 
aimed to compare the onset of metastasis in the cohort of patients that underwent RRP, 
only four patients in this group developed metastasis forcing us to include a second cohort 
of patients who developed metastasis during their follow-up and did not undergo RRP. 
Our goal was to have a significantly higher number of patients included in our database, 
however, a number of patients did not give their informed consent (Appendix A). Other 
subjects were lost because at the time of sectioning the tissue samples for our study, the 
portion of tissue with tumour was very small and had been used almost completely for 
either diagnosis or staging. Finally, another group of patients were diagnosed at different 
hospitals making it very difficult for us to have access to the tissues. Due to the above 
mentioned reasons we were forced to exclude a significant percentage of subjects from 
this study.
4.2.2 Rhamm compartmentalization and its functions
This is a novel study because it not only is the first to compare the full length version of 
Rhamm with an isoform that has been proven to be transforming and induce metastasis 
[38], but also because we are the only group that possesses a Rhamm -/- cell line that 
allowed us to identify individual characteristics of each isoform of Rhamm in terms of
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function and subcellular localization Despite the fact that this is a small study, we were 
able to demonstrate, at least partially, the mechanisms that make RhammA163 oncogenic. 
This study, along with others published by our group, link Rhamm with many o f the steps 
; required for tumour progression. Namely, we have demonstrated that Rhamm contributes 
to loss of contact inhibition o f growth, resistance to cell anchorage dependent 
programmed cell death, enhanced cell migration and invasion [38-42], and regulation of 
cell division by controlling mitotic spindle stability [43-45]. It is evident that this protein 
is an important player in the oncogenic process.
Because Rhamm is a coiled coil protein [46], the generation of specific antibodies can be 
difficult. At present, we are working on developing new monoclonal antibodies specific 
for Rhamm. A delay in the production of such reagents significantly slowed the data 
acquisition for my project. To overcome this problem, I developed this model in which I 
fused ZsGreen-Rhamm-FLAG tag for visualization purposes. Even though the system 
met our goal, making stably transfected ZsGreen-Rhamm-FLAG expressing cells was 
impossible since they lost their fluorescence overtime, making it very difficult for us to 
control which cells were still expressing our construct. Furthermore, in accordance with 
previous reports, our ZsGreen-Rhamm construct induced a blockage in the cell cycle 
making it impossible for us to perform cell proliferation studies. We hypothesize that the 
expression of Rhamm under the CMV promoter, which is very efficient and drives high 
protein production levels in the cell, negatively inpacts cell cycle progression. Both 
overexpression and underexpression of Rhamm have previously been shown by our 
laboratory to induce genomic instability and apoptosis in the former case. Our lab is
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currently developing a system under the control of a (3 actin promoter that has proven to 
be less toxic for our cells.
4.3 Future studies
The results obtained from these two studies open many possibilities for us to pursue in the 
future.
4.3.1 CD151 immu noreactivity predicts early biochemical failure and
metastasis in prostate cancer.
Arrangements are being made to assess the immunoreactivity o f CD151 in a significantly 
higher number prostate cancer tissue from both non-metastatic and metastatic patients. If 
the results of this new study are similar to those found here, we plan to-take advantage of 
our strategic position at the London Regional Cancer Program to propose a prospective 
project in which CD151 immunoreactivity be assessed at the time o f diagnosis to help 
physicians plan treatment options and then measure disease recurrence, onset o f 
metastasis and reduction in morbidity and adverse effects o f unnecessary therapeutic 
approaches. We are currently in the process of obtaining tissue samples from patients that 
underwent high intensity focussed ultrasound (HIFU) and cryotherapy as treatment for 
local radio-recurrent prostate cancer and that exhibited cancer recurrence after 6-8 months 
of treatment. CD151 immunoreactivity will be assessed and the results will be analysed to
determine if  there is any correlation between local recurrence and expression of the
¥
protein in this cohort.
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Additionally, we are planning on exploiting the potential of our 1A5 antibody to assess 
the presence and significance of CD151 expressing tumour microparticles inpatients with 
prostate cancer.
4.3.2 Rhamm compart me ntalization and its functions
The results obtained from the ZsGreen-Rhamm constructs open the road for many 
opportunities. The first step that our group is taking is the creation of these constructs 
under the control o f the P actin promoter in order to create stable cell lines expressing the 
construct. Also, interaction between the two isoforms can be evidenced in part by fusing 
one o f  them to a different fluorescent protein such as m-cherry or td-tomato. We also plan 
to use the stable cell lines to observe the dynamics of these isoforms in v ivo  in a wound 
healing environment using the chicken embryo model. The same model can also be used 
to. assess if  RhammA163 has an effect on tumour growth arrest after injection, 
intra/extravasation, proliferation and metastasis in an experimental metastasis assay.
In addition, experiments using a nuclear export signal (NES) to constitutively direct 
pERK out of the nuclei of the cell are currently being performed. The aim is to further 
confirm that Rhamm&163 not only favours pERK translocation to this compartment, but 
also induces its retention there promoting cell transformation.
■ . . - . t
Additionally ongoing are scratch wound assays to compare the migratory capacity that the 
two isoforms confer to our Rhamm-/- MEFs.
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Results o f these experiments will help to further elucidate the molecular mechanisms by 
which RhammA163 exerts its oncogenic functions.
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One way ANOVA-Tukey’s test ***p<0.009, n: 24
Supplemental figure 2.1 ZsGreen-Rhamm isoforms behave differently in 10T1/2 
fibroblasts than in Rhamm -/- cells. A) Confocal images of 10T1/2 cells transfected 
with ZsGreen RhammFL or ZsGreen-RhammA163. B) Fluorescence Recovery After 
Photobleaching (FRAP) analysis was performed in Rhamm -/- MEFs transfected with 
ZsGreen-Rhamm11' '1165 fusion. C) Pearsons correlation of co-localization of Rhamm -/- 
MEFs transfected with ZsG-RhammFL/ Al63 fusion and stained using mAbs to a and P 
tubulin and pERK (D) . For analysis, four regions of interest were delineated per cell on a 
total of 6 cells per group.
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Rhamm -/- MEFs + 
untagged RhammFL
Rhamm-/- MEFs + 
untagged RhammA163
Supplemental figure 2.2 ERK activation does not affect the distribution of ZsG- 
RhammFL/ Al63 fusion. A) Confocal imaging was performed after transfection o f ZsG- 
RhammFL/ A163 fusion on Rhamm KO MEFs that were previously stably transfected with 
constitutively active MEK. B) Rhamm basal expression does not affect the distribution of 
ZsG-Rhamm FL/ Al63 filslon. Confocal imaging was performed after transfection o f ZsG- 
RhammFL/ Al63 fusion on Rhamm KO MEFs that were previously stably transfected with 
either isoform of Rhamm. Scale bars, 20 pm.
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Supplemental figure 3.1 CD151 expression in adult tissues. CD151 expression levels 
were extracted from publically available expression dataset GDS3113 (n=3/tissue, Dezso 
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Appendix A: Format for phone informed Consent
Local Principal Investigator: Dr. J. Chin MD, FRCSC 
London Health Sciences Centre
PURPOSE
You have been invited to participate in a research study because you have previously 
been diagnosed with prostate cancer and have had a biopsy to confirm this. You may also 
have had a radical prostatectomy (total removal of your prostate) or a trans-urethral 
prostatectomy.
The purpose of this study is to examine your previously removed tissue from one of the 
methods described above and check it for the presence of a protein marker called CD 151.
Previous studies have shown that this protein may be a superior prognostic indicator for 
overall survival. Developing this kind of markers we will use the specimens also for 
future but presently unidentified markers. This may help us to understand the behavior of 
the prostate tumors.
PROCEDURES
If you agree to participate in the study please indicate so to the person that is calling you.




There will be no benefit to you from participating in this trial. The information collected 
from your participation may assist us in treating patients with prostate cancer in the 
future.
RISKS
There are no known risks associated with this study.
CONFIDENTIALITY
All information collected in this study will be kept strictly confidential. A study number 
will code your research records.
COMPENSATION (MEDICAL/FINANCIAL) TO BE PROVIDED
There is no payment to you for your participation in the study. By giving consent you are 
in no way waiving your legal rights or releasing the investigator from his legal and 
professional responsibilities.
OTHER INFORMATION
If you have any concerns regarding this study you can contact the Principal Investigator, 
Dr. J. Chin at or the Urology Research Office at For
questions concerning your rights as a research subject you may contact Dr. David Hill, 
Scientific Director, I^awson Health Research Institute at
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D ear Dr. Chin:
The Tissue and Archives comm ittee has approved your application for tissue for biomedical research, pending 
receipt o f a  copy of vour University o f W estern Ontario Research Ethics Boafd Approval, under the title:
TA # 462 - CD151 as a prognostic factor in prostate cancer.
Your request for tissue has been given the Tissue Application #  462 . Please refer to this number in any future 
correspondence.
Th e  R esearch Assistant has been advised that this protocol has been approved with a  3 section, limit per 
patient case w here there Es adequate tissue available and will aid you hereafter in obtaining the requested 
m aterials. %
Relevant technical charges will be billed directly to your office. Please see  the enclosed cost estimate. For 
funded research, paym ent is expected in full at your earliest convenience. P lease m ake certain that the 
appropriate funds have been reserved for this.
It is London Health Sciences Centre policy not to release original pathology materia! {slides or blocks).
It is the responsibility o f each investigator to maintain the new  standards of privacy legislation.
Any publications should include acknowledgment o f the Department o f Pathology, London Health Sciences 
Centre.
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